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PROTOCOL SYNOPSIS 
Study Title A Multi-Center, Randomized, Controlled, Pivotal Study 
To Assess the Safety and Efficacy of A Selective 








The Selective Cytopheretic Device (SCD) is comprised of 
tubing, connectors, and a synthetic membrane cartridge. The 
device is connected in series to a commercially available 
Continuous Renal Replacement Therapy (CRRT) device. 
Blood from the CRRT circuit is diverted after the CRRT 
hemofilter through to the extra capillary space (ECS) of the 
SCD. Blood circulates through this space and it is returned to 
the patient via the venous return line of the CRRT circuit. 
Regional citrate anticoagulation is used for the entire CRRT 
and SCD blood circuits.   
 
The SCD-ARF is a synthetic membrane with the ability to 
bind activated leukocytes and when used in a continuous 
renal replacement extracorporeal circuit in the presence of 
regional citrate anticoagulation modulates inflammation. 
 
Rationale Our primary hypothesis is that up to seven sequential 24-
hour SCD treatments will improve survival in patients with 
Acute Kidney Injury (AKI) as compared to CRRT alone 
(standard of care).  Further, SCD therapy may reduce the 
duration of maintenance dialysis secondary to AKI due to 
acute tubular necrosis (ATN).  ATN is an acute reversible 
process and if not reversed in three months, it may not be 
reversed at all. [1, 2] Studies suggest that approximately 
10% of AKI patients do not recover renal function [3, 4] and, 
therefore, require chronic dialysis. 
 
Importantly, acute kidney injury is a highly lethal condition 
in critically ill patients. Despite improvements in acute 
medical care and advances in dialysis therapies, the mortality 
rate during the past four decades of this condition has not 
improved. Critically ill patients with AKI in hospital ICU 
settings have mortality rates of 50 to 80%. [5 - 9] 
 
AKI promotes a systemic inflammatory response syndrome 
(SIRS) which results in systemic microvascular damage and, 
if severe, multi-organ dysfunction. [10, 11] Activated 
circulating leukocytes play a central role in this process. [12] 
Leukocytes, especially neutrophils, are major contributors to 
the pathogenesis and progression of many inflammatory 
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disorders, including SIRS, sepsis, ischemia reperfusion 
injury, and acute respiratory distress syndrome (ARDS). 
Many therapeutic approaches are under investigation to limit 
the activation and tissue accumulation of leukocytes at sites 
of inflammation to minimize tissue destruction and disease 
progression. [13-15]  
 
Primary Objective To achieve a clinically and statistically significant 
improvement on all-cause mortality through Day 60 post 





To assess the effect of SCD treatment on various measures 
of patient clinical outcome and to evaluate the integrity of 
the SCD-ARF and patient safety in SCD treatments from the 
time of initiation of therapy to as many as seven consecutive 
24-hour SCD treatments. 
 
Primary Endpoints The Primary Clinical Efficacy endpoint in this trial is time to 




Renal Replacement Therapy dependency at day 60. 
Mortality at day 28. 
Number of ventilator free days (VFD) at day 28. 




Patients receiving care in the Intensive Care Units of each 
participating hospital will be screened daily and identified 
for participation in the trial. 
 
Study Design This is a two-arm, randomized, open-label, controlled multi-
center Pivotal study.   
 
Approximate 
Number of Subjects 
 
Up to 344 patients will be enrolled in this study. 
Approximate 
Number of Centers 
 
Up to 30 Clinical Centers in the United States will 
participate in this study. 
Duration of Subject 
Participation 
Each patient will be followed for 60 days following 
randomization. 
 
Inclusion Criteria 1. A patient, or legal representative, has signed a written 
informed consent form. 
2. Must be receiving medical care in an intensive care unit 
(e.g., ICU, MICU, SICU, CTICU, Trauma). 
3. Age 18 to 80 years. 
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4. Females of child bearing potential who are not pregnant 
(confirmed by a negative serum pregnancy test) and not 
lactating if recently post-partum. 
5. Must be receiving and tolerating CRRT therapy for a 
minimum of 4 hours, but not longer than 24. 
6. Expected to remain in the ICU for at least 96 hours after 
evaluation for enrollment. 
7. A clinical diagnosis of ATN due to hemodynamic or 
toxic etiologies. ATN is defined as Acute Kidney Injury 
occurring in a setting of acute ischemic or nephrotoxic 
injury with oliguria (average <20 mL/hr) for >6–12 hours 
or: an increase in serum creatinine ≥2 mg/dL (≥1.5 
mg/dL in females) over a period of ≤4 days. (Note: 
Prerenal, hepatorenal, vascular, interstitial, glomerular, 
and obstructive etiologies are excluded on clinical or 
other diagnostic grounds.) 
8. At least one non-renal organ failure (SOFA organ system 
score ≥2), as defined in Appendix A or presence (proven 
or suspected) of sepsis as defined in Appendix C. 























1. Irreversible brain damage based on available historical 
and clinical information. 
2. Presence of a renal transplant at any time. 
3. Non-renal organ transplantation within six months of 
screening. 
4. Presence of preexisting advanced chronic renal failure 
(Stage 5) prior to this episode of AKI. Preexisting 
Chronic Renal Failure is defined by dialysis dependence 
or as a baseline serum creatinine >2.5 mg/dL (men) or 
>2.0 mg/dL (women).  
5. AKI occurring in the setting of burns, obstructive 
uropathy, allergic interstitial nephritis, acute or rapidly 
progressive glomerulonephritis, vasculitis, hemolytic-
uremic syndrome, thrombotic thrombocytopenic purpura 
(TTP), malignant hypertension, scleroderma renal crisis, 
atheroembolism, functional or surgical nephrectomy, 
hepatorenal syndrome, cyclosporine or tacrolimus 
nephrotoxicity. 
6. Metastatic malignancy which is actively being treated or 
may be treated by chemotherapy or radiation during the 
subsequent three month period after study therapy. 
7. Chronic immunosuppression (e.g., HIV/AIDS, chronic 
glucocorticoid therapy >20 mg/day prednisone 
equivalent on a chronic basis). The acute use of 
glucocorticoids is permissible. 
8. Severe liver failure as documented by a Child-Pugh Liver 
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Failure Score >12 (see Appendix F). 
9. Do Not Resuscitate (DNR) status. 
10. Comfort measures only. 
11. Patient is moribund or for whom full supportive care is 
not indicated. 
12. Patient not expected to survive 28 days because of an 
irreversible medical condition. (This is not restrictive to 
AKI, and may include situations such as the presence of 
irreversible brain damage, untreatable malignancy, 
inoperable life threatening condition, or any condition to 
which therapy is regarded as futile by the PI.) 
13. Any medical condition that the Investigator thinks may 
interfere with the study objectives. 
14. Physician refusal. 
15. Patient is a prisoner. 
16. Dry weight of >150 kg. 
17. More than one hemodialysis treatment during this 
hospital admission or prior to transfer from an outside 
hospital.  
18. Platelet count <30,000/mm3 at time of screening.  
19. Concurrent enrollment in another interventional clinical 
trial. Patients enrolled in clinical trials where only 
measurements and/or samples are taken (NO TEST 
DEVICE OR TEST DRUG USED) are allowed to 
participate. 
20. Use of any other Investigational drug or device within the 
previous 30 days. 
 
Evaluation Plan The primary endpoint in this trial is time to all-cause 
mortality through 60 days post-randomization. The primary 
analysis is the assessment of difference between the 
experimental treatment (CRRT+SCD) and the control 
treatment (CRRT alone) on the primary endpoint, and the 
assessment of this difference will be carried out at an 
overall two-sided 0.05 level of significance. Statistical 
treatment comparisons on secondary endpoints will also be 
carried out at an overall two-sided 0.05 level of 
significance, unless otherwise specified. Statistical analyses 
will be carried out using SAS version 9.1 or higher, and 
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LIST OF ABBREVIATIONS 
 
AE Adverse Event 
AKI Acute Kidney Injury 
ARDS Acute Respiratory Distress Syndrome 
ARF Acute Renal Failure 
ATN Acute Tubular Necrosis 
Cai Ionized Calcium 
CBC Complete Blood Count 
CRF Case Report Form 
CRO Clinical Research Organization 
CRRT Continuous Renal Replacement Therapy 
CTICU Cardiothoracic Intensive Care Unit 
CVVH Continuous Veno-Venous Hemofiltration 
CVVHD Continuous Veno-Venous Hemodialysis 
CVVHDF Continuous Veno-Venous Hemodiafiltration 
ECS Extra Capillary Space 
ICU Intensive Care Unit 
HPTC Human Proximal Tubular Cells 
LOS Length of Stay 
MICU Medical Intensive Care Unit 
PEEP Positive End Expiratory Pressure 
QOL Quality of Life 
RAD Renal  Assist Device 
SAE Serious Adverse Event 
SCD Selective Cytopheretic Device 
SICU Surgical Intensive Care Unit 
SIRS Systemic Inflammatory Response Syndrome 
SOFA Sequential Organ Failure Assessment 
WBC  White Blood Cell 
UADE Unanticipated Adverse Device Effect 
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1. INTRODUCTION 
The Selective Cytopheretic Device (SCD) is comprised of tubing, connectors, and a 
synthetic membrane cartridge. The device is connected in series to a commercially 
available Continuous Renal Replacement Therapy (CRRT) device. Blood from the 
CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary 
space (ECS) of the SCD. Blood circulates through this space and it is returned to the 
patient via the venous return line of the CRRT circuit. Regional citrate 
anticoagulation is used for the entire CRRT and SCD blood circuits.   
 
The SCD-ARF is a synthetic membrane with the ability to bind activated leukocytes 
and when used in a continuous renal replacement extracorporeal circuit in the 
presence of regional citrate anticoagulation modulates inflammation. 
 
 
Figure 1 Schematic of the CRRT circuit and SCD 
 
1.1. RATIONALE FOR THERAPY 
Our primary hypothesis is that up to seven sequential 24-hour SCD treatments 
will improve survival in patients with Acute Kidney Injury (AKI) as compared to 
CRRT alone (standard of care).  Further, SCD therapy may reduce the duration of 
maintenance dialysis secondary to AKI due to acute tubular necrosis (ATN).  
ATN is an acute reversible process and if not reversed in three months, it may not 
be reversed at all. [1, 2] Studies suggest that approximately 10% of AKI patients 
do not recover renal function [3, 4] and, therefore, require chronic dialysis. 
 
Importantly, acute kidney injury is a highly lethal condition in critically ill 
patients. Despite improvements in acute medical care and advances in dialysis 
therapies, the mortality rate during the past four decades of this condition has not 
improved. Critically ill patients with AKI in hospital ICU settings have mortality 
rates of 50 to 80%. [5 - 9] 
 
AKI promotes a systemic inflammatory response syndrome (SIRS) which results 
in systemic microvascular damage and, if severe, multi-organ dysfunction. [10, 
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11] Activated circulating leukocytes play a central role in this process. [12] 
Leukocytes, especially neutrophils, are major contributors to the pathogenesis and 
progression of many inflammatory disorders, including SIRS, sepsis, ischemia 
reperfusion injury, and acute respiratory distress syndrome (ARDS). Many 
therapeutic approaches are under investigation to limit the activation and tissue 
accumulation of leukocytes at sites of inflammation to minimize tissue destruction 
and disease progression. [13-15]  
 
2. PRIOR CLINICAL EXPERIENCE 
2.1. PHASE II RENAL ASSIST DEVICE STUDY (RAD003 IND NUMBER 11077) 
CytoPherx predecessor, RenaMed, had implemented and participated in Phase I/II 
and Phase II clinical studies of renal cell therapy with the cellular-based Renal 
Assist Device (RAD) in ICU patients with AKI and multi-organ failure.  The 
devices used in these studies were seeded with human renal proximal tubule cells 
isolated from kidneys donated for cadaveric transplantation, but found to be 
unsuitable for transplantation due to anatomic or fibrotic defects.  The studies 
incorporated acellular cartridges (currently referred to as SCD) as a control and 
therefore provided supporting evidence for the safety of treatment with the SCD. 
 
A Phase IIb clinical study of the RAD was undertaken to evaluate a commercial 
cell manufacturing process and the addition of citrate regional anticoagulation. 
Small subsets of patients were treated with citrate receiving either an acellular or 
a cell-containing cartridge. Subsets were analyzed to compare the mortality rates 
in patients treated with acellular cartridges (SCD) with systemic heparin 
anticoagulation or citrate regional anticoagulation. 
 
Twenty-four patients were randomly assigned to the acellular cartridge (SCD) 
group that received either systemic heparin (n = 12) or regional citrate (n = 12) 
anticoagulation. As detailed in Table 1, baseline demographics of the subgroups 
were comparable with similar SOFA scores, organ-failure number, and incidence 
of sepsis between the two groups.  
 
 Heparin (n=12) Citrate (n=12) 
Age (y) 61.4 ± 1.4 57.7 ± 5.3 
Male/Female 10/2 7/5 
SOFA 13.4 ± 1.1 12.2 ± 0.9 
MOF 4.17 ± 0.46 3.33 ± 0.36 
Sepsis 58% 58% 
Notes: MOF = multi-organ failure number, SOFA = sequential organ failure assessment score. 
Organ failure defined as SOFA organ-specific score ≥ 2 
Table 1 RAD003 Baseline Subgroup Demographics 
Figure 2 displays the survival plot for the two subgroups. The mortality rate in the 
heparin patient group was 50% vs. 25% in the citrate-treated group (n = 12 for 
each treatment arm) at 28 days and 75% vs. 33%, respectively, at 90 days (Chi-
square < 0.05). 
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Figure 2 RAD003 Survival plot 
Table 2 summarizes the reasons for discontinuation of the continuous venovenous 
hemofiltration (CVVH) + acellular cartridge (SCD) in the AKI patients along 
with the duration of therapy on the device. The median duration of treatment on 
the device was 62 hours. 
 
Failure of CVVH circuit 30% 
Completed 72 hrs of therapy 26% 
Failure of acellular device 17% 
Improvement in clinical status 9% 
Concomitant medical conditions 9% 
Withdrawal of participation 4% 
Device-related medical events 4% 
Death 0% 
Notes: Median time of therapy = 2.6 d (62 h) 
                       Table 2 Reasons for discontinuation of CVVH+Acellular Cartridge (currently refer to as SCD) therapy 
(n=24) 
Device-related medical events resulted in discontinuation of one patient assigned 
to receive the SCD (4%). The reason for discontinuation of the CVVH + acellular 
cartridge (SCD) in the heparin group was a low platelet count. Thrombocytopenia 
is a recognized complication of critically ill patients in the ICU. Review of the 
total white blood cell, neutrophil, and platelet counts obtained daily during the 
treatment period did not show any substantive change from baseline values in 
either of the two groups. Except for the one patient noted above, none of the 
patients developed absolute neutropenia or thrombocytopenia during the treatment 
period. 
 
For patients listed as having ―Failure of the acellular Device,‖ regardless of 
treatment group, the case report form (CRF) indicated that this was due to clotting 
of the CVVH circuit. Thus, in each case, clotting originated in the CVVH circuit 
and then propagated to the cellular or acellular circuit cartridge. Combining the 
Heparin 
Citrate 
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―Failure of the CVVH Circuit‖ and ―Failure of the Acellular Device‖ categories 
the incidence of clotting was 47% in the acellular control group before the 
complete 72-hour treatment plan, with median time of blood flow patency of the 
circuit of 62 hours. Compared to single-cartridge continuous renal replacement 
therapy (CRRT), this time-to-failure rate is favorable. [16-19] 
 
Immuno-fluorescent staining of a small number of SCD cartridges after patient 
treatment demonstrated adherent leukocytes on the outer surface of the hemofilter 
membranes. Elution of cells from the SCD’s ECS demonstrated that >98% of the 
cells were neutrophils. 
 
All serious adverse events (SAEs) during the first 28 days after randomization 
were reported to the Medical Monitor within 24 hours of the event. The events 
were initially reported in a blinded manner, but after study completion, the blind 
was broken and the SAEs were analyzed by treatment group. SAEs were reported 
in 57.1% (16 of 28) patients receiving CVVH + RAD and in 52.0% (13 of 25 
patients) receiving CVVH + acellular cartridge (SCD).  
 
The reported SAEs were consistent with a seriously ill ICU patient population 
with AKI receiving CVVH. When analyzed by body system, a higher frequency 
of serious cardiac-related adverse events was observed in the RAD treatment 
group (7 of 28; 25%) compared to the control acellular treatment group (2 of 25; 
8%). The SAEs included cardiac arrest (10.7% and 4.0%, respectively), 
cardiopulmonary arrest (10.7% and 0%, respectively), cardiopulmonary failure 
(0% and 4.0%, respectively), and electromechanical dissociation (3.6% and 0%, 
respectively). 
 
2.2. ESRD SAFETY AND BIOINFLAMMATORY ASSAY STUDY 
A study of the SCD was conducted at the Henry Ford Hospital in Detroit, 
Michigan entitled ―A Phase I/II Trial of a Two-Cartridge Hemodialysis System on 
Inflammatory Markers in Chronic Hemodialysis Subjects‖. This study was 
designed to determine what effect one treatment with the SCD would have on the 
reduction of bioinflammatory markers such as cytokines IL-2, IL-6, IL-8 and IL-
10 and white cell activation in chronically inflamed End Stage Renal Disease 
(ESRD).  The study enrolled fifteen subjects at one site, with four of the original 
15 patients re-enrolled in what was called ―Amendment 2‖. 
 
Fifteen chronic hemodialysis (HD) patients with elevated CRP levels were treated 
for four hours under standard HD with systemic heparin anticoagulation and, at 
their next dialysis treatment session, received standard HD plus SCD therapy with 
regional citrate anticoagulation. The 15 patients have completed the study 
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Fever 1 0 
Chills 2 0 
Headache 1 0 
Nausea 3 0 
Vomiting 2 1 
Diarrhea 1 0 
Dizziness 1 1 
Visual Disturbances 0 1 
Lethargy 0 1 
Itching 1 0 
Latent TB infection 1 0 
Cough 1 0 
Left cheek swelling 1 0 
Decreased hemoglobin 1 1 
Increased CRP level 2 0 
Neck swelling cellulites 0 1 
Ankle sprain 0 1 
Replacement of left 
dysfunctional IJ catheter for HD 
1 0 
Dialysis catheter fell off during 
sleep 
0 1 
Muscle cramp 0 1 
Chest pain 0 1 
Clotted extracorporeal system. 
350 ml blood loss 
0 1 
L Upper quadrant pain 0 1 
Decreased WBC 0 1 
Table 3 Report of Adverse Events - ESRD trial 
Additional data analysis and the assay of various biomarkers remain in progress.  
 
2.3. AKI SAFETY, MORTALITY AND DEVICE INTEGRITY STUDY (CHINA) 
2.3.1. STUDY DESIGN AND OBJECTIVE 
A study of the SCD was conducted at the Huashan Hospital in Shanghai, China 
entitled ―An Exploratory Clinical Study to Assess Safety and Efficacy of the 
Double Hemofiltration Cartridge Device (DCD) in Patients with Acute Renal 
Failure‖. 
 
This study was a prospective, non-randomized, interventional study designed to 
evaluate the effect of treatment with the SCD on in-hospital mortality in the 
acute renal failure population being treated with continuous veno-venous 
hemofiltration (CVVH) with regional citrate anticoagulation. All subjects 
received standard intensive care treatment for patients undergoing CVVH in 
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addition to the SCD treatment. CVVH treatment was delivered via standard 
modes, i.e. 2.5L/hour replacement fluid dose pre-dilution. 
 
2.3.2. CITRATE PROTOCOL 
The hypotonic trisodium citrate (4%, 136 mmol/L) was infused pre-filter at a 
fixed ratio of 3.5-4.5 mmol/L to the blood flow by means of a three-way 
stopcock at the junction of the catheter. The calcium-free replacement fluid 
delivered at the rate of 2.5L/h was composed of 121 mmol/L sodium, 3.2 
mmol/L potassium, 0.75mmol/L magnesium, 109 mmol/L chloride, 7 mmol/L 
bicarbonate and 250mg/dL of dextrose. The calcium chloride solution (5%, 
340mmol/L calcium) was infused into the venous return by means of a three-
way stopcock at the junction of the catheter.  
 
Calcium chloride was replaced at 1.0 mmol/L of blood flow as an initial dose. 
Systemic ionized calcium was checked repeatedly, and accordingly, calcium 
infusion rate was adjusted to maintain the level of calcium in circuit between 
0.2-0.4 mmol/L and ionized systemic calcium at normal range (1.0-1.2 
mmol/L). 
 
2.3.3. PATIENT POPULATION 
Adult male and female (non-pregnant) patients, aged 18-80 years, requiring 
either CVVH or CVVHD for the treatment of acute kidney injury secondary to 
acute tubular necrosis (ATN) were enrolled. ATN was defined as acute kidney 
injury occurring in a setting of acute ischemic or nephrotoxic injury and oliguria 
(<20 ml/hr) for > 24 hours or an increase in serum creatinine > 2 mg/dL (> 1.5 
mg/dL in females) over a period of < 4 days. 
 
2.3.4. STUDY ENDPOINTS 
In this exploratory clinical study three domains of interest were designated, and 
within each of those domains both Key Endpoints and Exploratory Endpoints 
were pre-specified as noted below: 
 
2.3.4.1. CLINICAL EFFICACY 
The primary clinical efficacy endpoint was in-hospital all-cause mortality. In 
addition, urine output was assessed as a surrogate marker for renal recovery. 
Both of these clinical parameters were compared to data from historical 
controls from the PICARD dataset matched for age and SOFA score [20]. 
 
2.3.4.2. PATIENT SAFETY 
The domain of patient safety and tolerability was assessed based upon the 
occurrence of adverse events (all, related, unexpected serious, unexpected 
serious related) as well as with leukocyte and platelet levels. 
 
2.3.4.3. DEVICE INTEGRITY AND PERFORMANCE 
Several parameters of device integrity and performance were monitored 
including evidence of leakage, cracking, clotting and hemolysis. 
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2.3.5. STATISTICAL ANALYSIS 
In-hospital mortality data was compared between the SCD treated patients and 
the case-matched historical control using the Fisher exact test. Age and SOFA 
scores were compared between the latter groups using the paired T-test. 
Multiple regression analysis was performed with mortality as the dependant 
variable and the following independent variables in the regression equation: age, 
SOFA score, and average change in urine output over the first seven days 
during or after treatment, and treatment modality (SCD vs. CVVH historical 
cohort). Urine output and change in urine output between the SCD and controls 
were compared using ANOVA analysis. All other variables reported were 
analyzed using descriptive statistics only. 
 
2.3.6. RESULTS 
A total of 12 patients were enrolled in this study. Safety for this patient 









Hypercalcemia 9 1 
Thrombocytopenia 1 0 
Hypocalcemia 0 0 
Allergic Reaction 1 0 
Hypophosphatemia 2 0 
Hypernatrimia 1 0 
Table 4 Adverse Events Reported for all 12 patients (including 3 off protocol) 
Of the 12 patients enrolled in the study, three were enrolled outside of the 
inclusion/exclusion criteria.  Two of these patients were not expected to survive 
for 96 hours and the third had active cancer. Therefore, the analysis focuses on 
the remaining 9 patients and is described below. [21] 
 
The nine patients enrolled in the trial ―on protocol‖ did not differ from the case 
matched controls with respect to age and SOFA score (Table 5). The mortality 
for the case matched controls was 77.78%, while the observed mortality in the 
SCD treatment group was 22.22% (p = .027). Multiple regression analysis 
identified treatment with SCD as the only significant variable affecting 
mortality among age, SOFA score, and average change in urine output over the 
first seven days during or after treatment, and treatment modality (SCD vs. 
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Mean Std Dev Test p value 
Age 59.33 13.85 59.22 17.15 T-test 0.99 
SOFA 11 3.64 11.44 3.05 T-test 0.78 
Mortality 22.22%  77.78%  Fisher’s exact  0.027* 
                  Table 5 SCD mortality and demographics compared to PICARD case-matched controls 
Mean total urine output in the 9 subjects receiving SCD treatment increased 
from a baseline of approximately 500 ml/day to over 1,500/day by day 7 of 
treatment. While there was no statistically significant difference in the change in 
urine output over the treatment time between the SCD and control group, mean 
urine output increased over time in the SCD treated group and diminished over 
time in the PICARD case matched control group. 
 
In the 9 subjects analyzed on SCD treatment, no neutropenic events were 
reported. Mean WBC counts remained normal throughout treatment, with a 
mild decline noted upon initiation of therapy that was shown to rebound by day 
7.  
 
No bleeding events were reported. Average platelet counts remained in the 
functional range (above 50,000) throughout treatment, with a mild decline noted 
upon initiation of therapy that was shown to plateau by day 4 to an average 
platelet count of 75,000. 
 
Adverse events noted included hypercalcemia (8), hypocalcemia (1), 
hypophosphatemia (2), hypernatremia (1), and thrombocytopenia (1), with the 
last patient requiring a platelet transfusion upon a decline in platelet count 
below 20,000 (Table 6).  These events were not attributed to the device by the 
investigator, as they commonly occur with CRRT treatment.  Moreover, the 
thrombocytopenic AE was not reported as serious by the PI despite the 
necessity of platelet transfusion because there were no clinical sequelae of the 









Hypercalcemia 6 2 
Thrombocytopenia 1 0 
Hypocalcemia 0 1 
Allergic Reaction 1 0 
Hypophosphatemia 2 0 
Hypernatremia 1 0 
      Table 6  Adverse event reporting – China Study – n=9 patients 
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2.3.7. SUMMARY 
This non-randomized, single center pilot study evaluated the safety and efficacy 
of treatment with a selective cytopheretic device in patients with a conventional 
CRRT circuit.  SCD treatment significantly reduced all-cause, in-hospital 
mortality in ICU patients with AKI compared to case matched controls from a 
national dataset (PICARD). 
 
This improved survival was demonstrated to be independent of age and SOFA 
score. Treatment with the SCD was well tolerated with an adverse event profile 
expected for a seriously ill population in the ICU with AKI. The blood flow 
patency of the SCD was comparable to single-cartridge CRRT modalities. 
 
2.4. PILOT STUDY USA ARF-002 - IDE G090189 
 
The pilot study of the SCD device (ARF-002 Clinical Trial) was designed to 
evaluate the safety and effect of the SCD treatment after up to seven consecutive 
24 hour SCD treatments compared to historic data on in-hospital mortality and 
all-cause mortality at day 28, and day 60 in the acute renal failure population 
being treated with Continuous Renal Replacement Therapy (CVVH, CVVHD, 
CVVHDF) with regional citrate anticoagulation.  
The study was conducted in 6 Clinical Centers in the United States. Patients 
receiving care in the critical care units of each participating hospital were 
screened daily and identified for recruitment. 
 
2.4.1. NUMBER OF SUBJECTS ENROLLED 
A total of 35 subjects were enrolled by a total of 6 centers in the United States 
between May 2010 and January 2011.   
 
2.4.2. SAFETY 
A summary of all adverse events (AEs) observed in the 35 subjects are 
summarized in Table 7.  A total of 199 adverse events were observed in 33 of 
the 35 subjects.  Of these 199 AEs, 12 were deemed to be possibly related and 1 
deemed definitely related (as determined by the investigator) to the study 
therapy.  These included worsening coagulation defect, hypotension, 
neutropenia, DIC, thrombocytopenia, recurrent renal failure, hypophosphatemia, 
hypercalcemia, anemia, and cardiogenic shock.  (Thrombocytopenia is 
frequently encountered during administration of CRRT therapy alone [22] and 
neutropenia is a known consequence of critical illness and/or sepsis [23]).  
 
One of these 13 related events, one event was deemed to be ―definitely‖ related 
to therapy which was coded as ―Metabolic Alkalosis Secondary to Citrate.‖  
Although this was the name given to the event by the PI, the event in question 
was a case of severe hypocalcemia which resulted from the initiation of citrate 
anticoagulation and which resulted in termination of therapy 2 hours after 
initiation.  Citrate intolerance is a known side effect of citrate anticoagulation in 
the setting of liver disease.  In some patients, citrate quickly builds up and leads 
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to metabolic alkalosis and hypocalcemia [24].  In this subject, the citrate 
intolerance was quickly recognized and therapy was discontinued 2 hours after 
initiation. 
 
Two subjects experienced thrombocytopenia which was deemed possibly 
related to the therapy and one required platelet transfusions.  There were 8 
additional incidences of thrombocytopenia in 8 subjects that were deemed as 
unrelated by the PI.  Four of these 8 subjects required platelet transfusions. As 
stated above, thrombocytopenia is frequently encountered during administration 
of CRRT therapy alone [22] and is often a consequence of the types of critical 
illnesses (e.g., bone marrow suppression, SIRS, sepsis, drug reactions) observed 
in the ICU setting.  For example, in a retrospective analysis of a 71 patient 
cohort in the ICU on systemic heparin anticoagulation who received CRRT, 31 
patients (44%) experienced severe thrombocytopenia [22].   
 
 Of the 199 events, 34.7% were deemed to be mild and were experienced by 
60% of the subjects, 51.8% were moderate and experienced by 71% of the 
subjects and 13.6% were severe, experienced by 54% of the subjects.    The AEs 
observed were those that were expected for a critically ill patient population 
with acute renal failure and/or in an ICU setting. 
 
Adverse Events 
Number of Subjects with Events 
N (% of 35) 
Number of Events 
% of 199 (n/199) 
Total adverse events 33 (94%) 199 
 Serious adverse event 23 (66%) 14.1% (28/199) 
 Unanticipated Adverse Device Effect 0 (0%) 0.0% (0/199) 
 Relationship to Study*   
     Unrelated to study therapy 32 (91%) 93.5% (186/199) 
     Possibly related to study therapy 8 (23%) 6.0% (12/199) 
     Probably related to study therapy 0 (0%) 0.0% (0/199) 
     Definitely related to study therapy 1 (3%) 0.5% (1/199) 
 Outcome   
     Resolved w/ sequelae 14 (40%) 13.6% (27/199) 
     Resolved w/out sequelae 25 (71%) 64.3% (128/199) 
     Continuing 11 (31%) 11.1% (22/199) 
     Death 11 (31%) 5.5% (11/199) 
     Reported as Unknown 3 (9%) 5.5% (11/199) 
 Frequency   
     Single Episode 29 (83%) 54.3% (108/199) 
     Intermittent 16 (46%) 21.1% (42/199) 
     Continuous 16 (46%) 24.1% (48/199) 
     Reported as Unknown 1 (3%) 0.5% (1/199) 
 Severity   
     Mild 21 (60%) 34.7% (69/199) 
     Moderate 25 (71%) 51.8% (103/199) 
     Severe 19 (54%) 13.6% (27/199) 
*Subjects experienced more than one AE, therefore, numbers do not add up to N=22  
(number of subjects experiencing any adverse event). 
Table 7 Summary of Adverse Events ARF-002 
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Clinical outcomes for the 35 subjects enrolled are shown in Table 8. Death from 
any cause at Day 60 was 31.4%.  This compares very favorably with the greater 
than 50% mortality reported in the literature [25] for subjects with similar 
SOFA scores.   
 
Renal recovery was observed in all of the surviving subjects at Day 60.  The 
mean time to ICU discharge from the beginning of SCD therapy was 15.09.1 
days [CI 11.1,18.9] and the time to hospital discharge from the beginning of 







Primary Endpoint   
Death in hospital 28.6% (10/35) [14.6%,46.3%] 
Death from any cause by day 28 from time of enrollment 25.7% (9/35) [12.5%,43.3%] 
Death from any cause by day 60 from time of enrollment 31.4% (11/35) [16.9%,49.3%] 
Other Clinical Efficacy   
Time to ICU discharge (days) from enrollment 15.0±9.1 (23) [11.1,18.9] 
Time to hospital discharge (days) from enrollment 21.8±10.9 (22) [17.0,26.6] 
No. of subjects discharged from ICU by day 28 60.0% (21/35) [42.1%,76.1%] 
No. of subjects discharged from hospital by day 28 54.3% (19/35) [36.6%,71.2%] 
No. of subjects discharged from ICU by day 60 65.7% (23/35) [47.8%,80.9%] 
No. of subjects discharged from hospital by day 60 62.9% (22/35) [44.9%,78.5%] 
Renal Recovery to day 28* 73.1% (19/26) [52.2%,88.4%] 
Renal Recovery to day 60* 100% (24/24) [86.2%.100%) 
† The presented numbers refer to: for discrete variable, % (no. patients with events/ total no. available 
patients) for continuous variable, Mean±SD(N), where N is the number of available patients. 
* Does not include subjects who died (N=5 at day 28 and N=7 at day 60)   
Table 8 Clinical Efficacy Outcome ARF-002 
All safety data has been collected by the Clinical Research Organization (CRO), 
SAE and death notices are sent directly to CRO from the Principal Investigator 
with supporting source documentation. The CRO safety officer reviews this 
information, makes queries as necessary, and generates a narrative of the events 
for monthly safety reports that are sent to CytoPherx.  
 
3. PIVOTAL STUDY (PROTOCOL SCD-003) OBJECTIVES AND ENDPOINTS 
3.1. PRIMARY OBJECTIVE 
To achieve a clinically and statistically significant improvement on all-cause 
mortality through day 60 post randomization of CRRT + SCD treatment 
compared to CRRT alone 
 
3.2. SECONDARY OBJECTIVE 
To assess the effect of SCD treatment on various measures of patient clinical 
outcome, health economics and to evaluate the integrity of the SCD-ARF and 
patient safety in SCD treatments from the time of initiation of therapy to as many 
as seven consecutive 24-hour SCD treatments. 
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3.3. PRIMARY ENDPOINT 
The Primary Clinical Efficacy endpoint measure in this trial is time to all cause 
mortality through  60 day post randomization. 
 
3.4. SECONDARY ENDPOINTS 
 Renal Replacement Therapy dependency at day 60. 
 Mortality at day 28. 
 Number of ventilator free days (VFD) at day 28. 
 Mortality of Severe Septic patient sub-population at day 60. 
Secondary Endpoints are defined in Appendix D. 
 
4. STUDY DESIGN 
This is a two-arm, randomized, open-label, controlled multi-center Pivotal study. 
 
5. SELECTION OF PATIENT POPULATION 
5.1. PATIENT RECRUITMENT 
Up to 30 Clinical Centers in the United States will enroll up to 344 patients to 
participate in this clinical trial. Patients receiving care in the Intensive Care Units 
of each participating hospital will be screened daily and identified for 
participation in the trial.  
 
All patients that are screened for the study will be entered by the Study Staff on a 
screening log. If the patient is not enrolled, the screening log will include 
information explaining why enrollment did not take place (exclusion criteria, 
attending physician refusal, patient refusal, etc). 
 
All enrolled patients will receive standard intensive care treatment for patients 
undergoing CRRT or CRRT + SCD. Any mode of CRRT will be allowed 
(CVVH, CVVHD, and CVVHDF) following each participating clinical site’s 
protocol. The modality of CRRT is not expected to affect performance of the 
SCD.  
 
The Sponsor will provide each site with a CRRT device (B.Braun Diapact® 
CRRT System) to be used with each patient randomized either to the Control or 
Study Arms. The B.Braun® CRRT System is a compact, self-containing system 
for high-flow continuous or intermittent renal therapies. Some of the technical 
features of the Diapact include an integrated plate warmer for the heating of 
infusion and dialysate fluids and a single load cell weighing system which reduces 
the possibility of error and increases accuracy. The Sponsor will also provide all 
the tubing, SCD-ARF and hemofilters to be used during the observation period of 
this trial. 
 
Each participating clinical site is to use their regional citrate anticoagulation 
protocol for the CRRT and SCD-ARF circuits (Study Arm) and for the CRRT 
only (Control Arm). The recommended ionized calcium level (measured post 
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SCD-ARF) in the CRRT and SCD-ARF blood circuit should be between 0.25 and 
0.4 mmol/L. 
 
5.2. INCLUSION CRITERIA 
1. A patient, or legal representative, has signed a written informed consent form. 
2. Must be receiving medical care in an intensive care unit (e.g., ICU, MICU, SICU, 
CTICU, Trauma). 
3. Age 18 to 80 years. 
4. Females of child bearing potential who are not pregnant (confirmed by a negative 
serum pregnancy test) and not lactating if recently post-partum. 
5. Must be receiving and tolerating CRRT for a minimum of 4 hours, but not longer 
than 24 hours. 
6. Expected to remain in the ICU for at least 96 hours after evaluation for 
enrollment. 
7. A clinical diagnosis of ATN due to hemodynamic or toxic etiologies. ATN is 
defined as Acute Kidney Injury occurring in a setting of acute ischemic or 
nephrotoxic injury with oliguria (average <20 mL/hr) for >6–12 hours or: an 
increase in serum creatinine ≥2 mg/dL (≥1.5 mg/dL in females) over a period of 
≤4 days. (Note: Prerenal, hepatorenal, vascular, interstitial, glomerular, and 
obstructive etiologies are excluded on clinical or other diagnostic grounds.) 
8. At least one non-renal organ failure (SOFA organ system score ≥2), as defined in 
Appendix A or presence (proven or suspected) of sepsis as defined in Appendix 
C. 
9. All patients must be able to tolerate regional citrate anticoagulation. 
 
5.3. EXCLUSION CRITERIA 
1. Irreversible brain damage based on available historical and clinical information. 
2. Presence of a renal transplant at any time. 
3. Non-renal organ transplantation within six month of screening. 
4. Presence of preexisting advanced chronic renal failure (Stage 5) prior to this 
episode of AKI. Preexisting Chronic Renal Failure is defined as a baseline serum 
creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women).  
5. AKI occurring in the setting of burns, obstructive uropathy, allergic interstitial 
nephritis, acute or rapidly progressive glomerulonephritis, vasculitis, hemolytic-
uremic syndrome, thrombotic thrombocytopenic purpura (TTP), malignant 
hypertension, scleroderma renal crisis, atheroembolism, functional or surgical 
nephrectomy, hepatorenal syndrome, cyclosporine or tacrolimus nephrotoxicity. 
6. Metastatic malignancy which is actively being treated or may be treated by 
chemotherapy or radiation during the subsequent three month period after study 
therapy. 
7. Chronic immunosuppression (e.g., HIV/AIDS, chronic glucocorticoid therapy 
>20 mg/day prednisone equivalent on a chronic basis). The acute use of 
glucocorticoids is permissible. 
8. Severe liver failure as documented by a Child-Pugh Liver Failure Score >12 (see 
Appendix F). 
9. Do Not Resuscitate Status (DNR). 
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10. Comfort measures only. 
11. Patient is moribund or for whom full supportive care in not indicated. 
12. Patient is not expected to survive 28 days because of an irreversible medical 
condition. (This is not restrictive to AKI, and may include situations such as the 
presence of irreversible brain damage, untreatable malignancy, inoperable life 
threatening condition, or any condition to which therapy is regarded as futile by 
the PI.) 
13. Any medical condition that the Investigator thinks may interfere with the study 
objectives. 
14. Physician refusal. 
15. Patient is a prisoner. 
16. Dry weight >150 kg. 
17. More than one hemodialysis treatment during this hospital admission or prior to 
transfer from an outside hospital. 
18. Platelet count <30,000/mm3. 
19. Concurrent enrollment in another interventional clinical trial. Patients enrolled 
in clinical trials where only measurements and or samples are taken (NO TEST 
DEVICE OR TEST DRUG USED) are allowed to participate. 
20. Use of any other interventional drug or device within the previous 30 days. 
 
6. STUDY ACTIVITIES 
6.1. SCREENING PERIOD 
The screening period is the time period when a patient is identified, informed 
consent is obtained, and the patient is evaluated for inclusion in the clinical trial. 
Because of the critically ill nature of the study population, it is expected that the 
majority of patients will not be able to provide informed consent. Where subjects 
are unable to consent themselves, surrogate informed consent will be sought from 
the subject’s healthcare proxy or other equivalent legal representative. Only 
adverse events directly related to the screening procedures will be reported during 
this time. 
 
Medical history and test results must be analyzed to ensure the patient meets all 
eligibility criteria. Tests that are specific to this protocol (i.e. not standard of care) 
require the patient or legal representative to have provided written consent for 
participation.  
 
Any patients that do not meet study criteria, whether consent was obtained or not, 
will not be randomized and enrolled into the study. These patients will not be 




A centralized randomization system has been established with 24-hour 
availability to provide a mechanism to randomize subjects and enroll them in the 
study.  Once the patient meets all eligibility criteria, including being on CRRT 
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for a minimum of 4 hours, but no longer than 24, and has signed informed 
consent, the site will enter the patient into the randomization system.  
 
Patients will be randomized in a 1:1 allocation utilizing a random permuted block 
design into either the control or treatment arm, stratified by study center and the 
presence of severe sepsis or not. (Appendix C). This should occur as close to the 
start of the Observation period as possible while also allowing time for baseline 
tests and data to be completed before the patient has been on CRRT for 24 hours.  
Patients will then be considered enrolled in the study and given a study number. 
Randomization results will not be revealed to the clinical team and patient until 
immediately prior to start of first treatment.  
 
6.2.1. CONTROL ARM 
Patients randomized to the control arm will receive renal replacement therapy 
utilizing a CRRT device that is identical to that used for the SCD treatment, 
tubing and hemofilter provided by the Sponsor. Anticoagulation of the system 
will be done using the institution’s protocol for citrate anticoagulation. All 
patients in the control arm are required to use citrate as an anticoagulant. 
 
6.2.2. STUDY TREATMENT ARM 
Patients randomized to the study treatment arm will receive renal replacement 
therapy plus SCD using the CRRT device, first hemofilter, SCD-ARF, and all 
tubing provided by the sponsor. Anticoagulation of the CRRT and SCD system 
will be done using the institution’s protocol for citrate anticoagulation. All 
patients in the treatment arm are required to use citrate as anticoagulant. 
 
6.3. BASELINE PERIOD 
The Baseline Period begins at randomization and ends at the start of the 
Observation Period. The following information will be recorded as close to the 
start of the Observation Period as possible. Data from standard of care tests may 
be used as baseline data, as long as it is captured within the time frames noted.  
 
 Demographic Data 
o Date of birth 
o Gender 
o Race/ethnicity 
 Hospitalization Data 
o Hospital Admission Date 
o Hospital Admission Diagnosis 
o ICU Admission Date 
o ICU Admission Diagnosis 
 Vital Signs/Physical Assessment 
o Temperature 
o Blood Pressure, heart rate, body weight  
o EKG (within 12 hours prior to the start of Observation Period) 
o Sequential Organ Failure Assessment (SOFA Score) 
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o Physical Exam 
o Urine Output (previous 24 hours) 
 Clinical Laboratory Tests (within 12 hours prior to the start of 
Observation Period) 
o CBC with differential  
o BUN/Creatinine 
o Na, K, Cl, HCO3, Ca, Mg, Ionized Ca, PO4 
o ALT, AST, LDH, Bilirubin, ALP, Total Protein, Albumin, Glucose 
o PT, PTT, INR 
o Haptoglobin 
o Urinalysis (if urine available) 
 Respiratory  
o Status – Ventilator support (yes/no; date of intubation) 
o If on Vent: Mode, NO, FiO2, Settings (TV, PEEP, RR) 
o If on Vent with an arterial line: Arterial Blood Gas (12 hours prior to 
start of Observation Period) 
o If on Vent without an arterial line: Arterial Blood Gas (24 hours prior 
to start of Observation Period) 
o If not Vented: Supplemental oxygen requirements  
 Blood for Research 
o Blood sample will be sent to an outside laboratory for testing of 
biomarkers such as IL6, IL10, Elastase, and GCSF. 
 Other (Event-driven) 
o All the medications and blood products administered to the patient in 
the 24 hours prior to prior to start of Observation Period. 
o Adverse Events occurring since randomization, unless directly related 
to screening procedure 
o Diagnostic/Therapeutic Procedures in the 24 hours prior to start of 
Observation Period. 
o Microbiology/culture data 
 
6.4. STUDY OBSERVATION PERIOD 
The Study Observation Period begins when the patient starts Control or Study 
Therapy and will continue up to a maximum of 168 hours from the time of 
Observation Start. It is expected that the patient will begin the Observation Period 
before the patient has reached 24 hours on CRRT.  
 
This observation period has been broken into seven 24 hour time periods.  It ends 
when the patient has reached 168 hours in the observation period or when the 
patient meets the termination criteria outlined in section 7.2 as determined by the 
Principal Investigator or Medical Team at the participating Clinical Site. 
 
All tests are scheduled on a 24 hour cycle, or once a day, and can be scheduled to 
be drawn around each participating site’s ICU blood drawing schedule, with the 
exception of any test that requires a specific draw frequency. 
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The following information will be obtained for patients enrolled in both study 
arms and recorded during the study observation period on a daily basis unless 
otherwise specified: 
 
 Vital Signs/Physical Assessment 
o Temperature 
o Blood Pressure, heart rate – every 4 hours (+/- 1 hour) 
o Body weight  
o Sequential Organ Failure Assessment (SOFA Score) 
o Urine Output (previous 24 hours) 
o Net Fluid Balance (previous 24 hours) 
 Clinical Laboratory Tests 
o CBC with differential – every 8 hours (+/- 2 hours) 
o BUN, Creatinine 
o Na, K, Cl, HCO3, Ca, Mg, Ionized Ca,PO4 
o ALT, AST, LDH, Bilirubin, ALP, Total Protein, Albumin, Glucose 
o Haptoglobin (on the last day of therapy only) 
o PT, PTT, INR 
 Respiratory  
o Status – Ventilator support (yes/no; date of extubation) 
o If on Vent: Mode, FiO2, Settings- TV, PEEP, RR (q4h first 12 hrs (+/- 
30 min)  of observation period and then q12h (+/- 1 hour) thereafter) 
o If on Vent with an arterial line: Arterial Blood Gas (q4h first 12 hrs 
(+/- 30 min) and then q12h (+/- 1 hour)  thereafter) 
o If on Vent without an arterial line: Arterial Blood Gas (once per 24 
hours) 
o If not Vented: Supplemental oxygen requirements (q4h first 12 hrs (+/- 
30 min)  of observation period and then q12h (+/- 1 hour) thereafter) 
 Blood for Research 
o Collect at hours 24, 72, 120, and 168 (+/- 4 hours). If study 
observation period ends prior to hour 168, collect at end of study 
observation period. Blood for biomarkers will be collected as close as 
possible to the time of SCD scheduled changes in the days required 
(+/- 4 hours) if practical. 
o Blood sample will be sent to an outside laboratory for testing of 
biomarkers such as IL6, IL10, Elastase, and GCSF. 
 CRRT Parameters (Both study arms – start at hour 0)  
o Parameters include modality, blood flow rate, net fluid removal, 
dialysate or replacement solution flow rate, citrate infusion rate, 
calcium replacement rate  (every 6 hours +/- 1 hour) 
o System performance (circuit survival - event driven) 
o Post filter ionized calcium (every 6 hours +/- 1 hour) 
 SCD Performance (Treatment Arm Only – start at hour 0) 
o SCD-ARF performance (event driven) 
 Other (Event Driven) 
o All the medications and blood products administered to the patient. 
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o Adverse Events 
o Diagnostic/Therapeutic Procedures  
o Microbiology/culture data 
 
6.5. STUDY FOLLOW UP PERIOD 
6.5.1. POST END OF STUDY TREATMENT PERIOD 
This Study Follow Up period has been broken into seven 24 hour time periods.  
It starts when the patient has reached 168 hours in the observation period or 
when the patient meets the termination criteria outlined in section 7.2. It ends at 
168 hours or until ICU discharge, whichever comes first. (Except for SOFA, net 
fluid balance and pressor use, which are followed until ICU discharge or Day 
28, whichever comes first and microbiology/culture data which will be collected 
until hospital discharge or Day 60, whichever comes first.)  
Record the following data daily in the Study Follow Up Period unless otherwise 
noted: 
 
 Vital Signs/Physical Assessment 
o Blood pressure and heart rate  
o SOFA Score (record until ICU discharge or Day 28) 
o Physical Exam (first 24 hours only) 
o Body weight and temperature  
o EKG (first 24 hours only)  
o Urine Output (from previous 24 hours) 
o Net fluid balance (record until ICU discharge or Day 28 - from 
previous 24 hours) 
 Clinical Laboratory Tests (first 24 hours only) 
o CBC with differential  
o BUN, Creatinine  
o Na, K, Cl, HCO3, Ca, Mg, Ionized Ca,PO4  
 Respiratory  
o Status – Ventilator support (yes/no)  
o If on Vent: Mode, FiO2, Settings- TV, PEEP, RR 
o If on Vent with an arterial line: Arterial Blood Gas  
o If not Vented: Supplemental oxygen requirements  
 Renal Replacement Therapy status 
o RRT status  
 Other (Event Driven) 
o All the medications and blood products administered to the patient. 
o Pressor Usage (record until ICU discharge or Day 28) 
o Diagnostic/Therapeutic Procedures 
o Adverse Events 
o Microbiology/culture data (record until hospital discharge or Day 60) 
 
6.5.2. DAY 28 POST RANDOMIZATION 
This visit may be done via telephone call or office visit. Please record the 
following information on day 28 (+7 days) following enrollment: 
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o Blood pressure, heart rate and temperature (if known) 
o Presence of mechanical ventilation (since last visit) 
o Presence of renal replacement therapy (since last visit) 
o Adverse events (since last visit) 
o Serum creatinine (if an office visit takes place) 
 
6.5.3. DAY 60 POST RANDOMIZATION 
This visit may be done via telephone call or office visit. Please record the 
following information on day 60 (+7 days) following randomization: 
o Blood pressure, heart rate and temperature (if known) 
o Presence of mechanical ventilation (since last visit) 
o Presence of renal replacement therapy (since last visit) 
o ICU discharge date 
o Hospital discharge date 
o Adverse events (since last visit) 
o Serum creatinine (if an office visit takes place) 
o SF36v2 Quality of Life Questionnaire  
 
7. TREATMENT INTERRUPTIONS – DISCONTINUATION CRITERIA 
7.1. TREATMENT INTERRUPTION CRITERIA 
The SCD is to be used continuously along with CRRT and changed every 24 
hours or at anytime the circuit exhibits significant clotting that impairs the 
functionality of the circuit. For patients randomized to either arm of the study, 
each participating site will follow their institution’s protocol or standard of care in 
regard to replacement of the CRRT hemofilter and/or tubing. 
In the event that a procedure is needed (e.g. CT-Scan, MRI), the CRRT or 
CRRT+SCD treatments may be interrupted for a maximum of 6 hours 
(cumulative) per 24 hour period. Cumulative interruption of greater than 6 hours 
in either the treatment or control arm will trigger the end of Observation Period 
and immediate initiation of the Follow-up period.  These patients will not be 
removed from the study unless consent is withdrawn.   
 
7.2. TREATMENT DISCONTINUATION CRITERIA 
7.2.1. CLINICAL CRITERIA 
Patients may be withdrawn from therapy (control or treatment) prior to hour 168 
for a variety of reasons. When therapy is discontinued prior to hour 168, the 
follow-up period will immediately begin and data will continue to be collected 
per protocol. 
 
The Principal Investigator will assign a primary reason for therapy termination 
utilizing the following categories, and if appropriate, one or more subcategories: 
 
1. Improvement in Clinical Status  
o If a patient’s condition improves (e.g. renal condition has 
improved to the extent that CRRT can be discontinued or 
hemodynamic status has improved so that the dialysis modality 
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can be changed from CRRT to IHD) treatment may be 
discontinued before the 168 hour treatment period. The 
decision to discontinue treatment based upon improvement in 
clinical status will be made by the Principal Investigator. 
 
2. CRRT related medical events 
o Such as persistent leukopenia, neutropenia or 
thrombocytopenia based upon PI’s clinical assessment of 
relationship to control arm. 
 
3. SCD related medical events 
o Such as persistent leukopenia, neutropenia or 
thrombocytopenia based upon PI’s clinical assessment of 
relationship to SCD.  
 
4. CRRT Failure/Malfunction 
o Failure of the CRRT device and/or circuit, including inability 
to maintain vascular access that requires treatment to be 
discontinued prior to hour 168 of therapy. 
 
5. SCD Failure/Malfunction 
o Any failure of the SCD-ARF that requires treatment to be 
discontinued prior to hour 168 of therapy—e.g. clotting or 
evidence of leakage in the SCD-ARF or inability to maintain a 
patent circuit. 
 
6. Death, including withdrawal of life support 
 
7. Concomitant Medical Conditions 
o Need for medical, surgical or diagnostic procedures that 
necessitate discontinuation of CRRT or CRRT + SCD 
treatment for longer than the allowable 6 hours per 24 hour 
period. 
8. Other 
o Any other reason that the Principal Investigator deems 
appropriate for discontinuation from the Study Observation 
period must be documented. 
 
7.2.2. NON-CLINICAL 
 Withdrawal of participation from study observation period 
Patients may withdraw their consent to participate in the study 
observation period (CRRT or CRRT + SCD) at any time. If the patient 
wishes to remain in the clinical study, the follow-up period will 
immediately begin at the termination of study observation period. All 
data will continue to be collected per protocol. 
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The Principal Investigator will notify the Sponsor’s Chief Medical 
Officer or designee within 24 hours of withdrawal of consent. 
 
 Withdrawal of consent 
If a patient or legal representative withdraws consent, all protocol related 
activities will be immediately discontinued. If study therapy 
(CRRT+SCD) is being administered at the time of withdrawal, normal 
procedures will be followed for CRRT+SCD therapy discontinuation 
(please see SCD Operator’s Manual). No further study activity will be 
conducted. 
 
The Principal Investigator will notify the Sponsor’s Chief Medical 
Officer or designee within 24 hours of withdrawal of consent. 
 
8. CLINICAL TRIAL TERMINATION CRITERIA 
The Sponsor reserves the right to terminate the clinical trial for safety or 
administrative reasons at any time. If the Sponsor, Principal Investigator, Data Safety 
Monitoring Board (DSMB), Institutional Review Board (IRB), or Food and Drug 
Administration (FDA) officials discover conditions during the study indicating that 
the trial or participation by a clinical site should be discontinued, this action may be 
taken after appropriate consultation between the Sponsor and the Investigators. 
 
Conditions that may warrant discontinuation of the trial at a specific clinical site may 
include the following: 
 Failure of the Investigator to enroll patients into the trial at an acceptable rate 
(as defined and agreed upon between the Investigator and the Sponsor). 
 Failure of the Investigator to comply with the pertinent FDA regulations. 
 Submission of false information by the Investigator from the research facility 
to the Sponsor or the FDA. 
 
Conditions that may warrant discontinuation of the trial may include, but are not 
limited to, the following: 
 Discovery of an unexpected, serious or unacceptable risk to the patients 
enrolled in the study. 
 Decision on the part of the Sponsor to suspend or discontinue testing, 




9.1. ADVERSE EVENTS 
An Adverse Event is any sign, symptom, illness, clinically significant abnormal 
laboratory value or other adverse medical event that appears for the first time or 
worsens in a subject (control or treatment arm) during this clinical study, 
regardless of whether or not it is considered related to the device. 
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9.2. SERIOUS ADVERSE EVENTS 
Any Adverse Event, whether considered study-treatment related or not, which fits 
any of the criteria below, is considered a serious adverse event (SAE): 
 Results in death 
 Is life-threatening (meaning that the patient was at risk of death at the time of 
the event; this does not refer to an event which might have caused death if it 
had occurred in a more severe form) 
 Requires in-patient hospitalization or prolongs the existing hospitalization 
 Is a persistent disability/incapacity 
 Is a congenital anomaly or birth defect 
 Is considered an important medical event by the Principal Investigator (e.g., 
surgery, return to ICU, emergency procedures) 
 
9.3. UNANTICIPATED ADVERSE DEVICE EFFECT 
Unanticipated adverse device effect (UADE) is any serious adverse effect on 
health or safety, any life-threatening problem or death caused by, or associated 
with a device, if that effect, problem, or death was not previously identified in 
nature, severity, or degree of incidence in the application; or any other 
unanticipated serious problem associated with a device that relates to the rights, 
safety, or welfare of subjects. 
 
9.4. ANTICIPATED ADVERSE EVENT 
Co-morbidities and symptoms/laboratory/physiological deviations normally 
associated with pre-existing conditions (e.g., diabetes, ASHD, other C-V 
conditions, pneumonia, dialysis shunt problems, neurologic deficits) are 
considered ―anticipated adverse reactions.‖ The investigator is required to take 
special care in differentiating concomitant illness events from those related to the 
randomized therapy by use of patient history, relationship to treatment time and 
cartridge integrity, and other characteristics of clinical circumstances present at 
the time of the adverse experience, including drug interactions of concomitant 
medications and effects of surgical and/or medical procedures.  
 
Adverse events associated with CRRT or underlying critical illness are also to be 
considered ―anticipated‖.  Such events include, but are not limited to: 
thrombocytopenia, hyponatremia, hypokalemia, hypo- or hypercalcemia, hypo- or 
hyperglycemia, air embolism, hypotension, hemolysis, increased oxygenation 
requirements, leukopenia, arrhythmias, hypothermia, lactic acidosis, temporary 
decrease in cardiac output or cardiac index, disruption of skin integrity, bleeding, 
shock, bacteremia, hypotension, and death. 
 
There are many anticipated events in the ICU patient that are not listed here. Any 
questions as to the expectedness of an adverse event will be discussed with 
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9.5. CAUSALITY 
All randomized patients must have all AEs assessed for causality (probability that 
the AE may have been caused by the study treatment) by the Principal 
Investigator. The following definitions for causality assessment will be used in 
this study: 
 
9.5.1. DEFINITELY RELATED 
A clinical event, including a significant change in a laboratory test, that occurs 
in a plausible time relationship to the SCD treatment or other protocol-required 
activity, and which cannot be explained by concurrent disease or other drugs, 
chemicals, or procedures and that follows a clinically reasonable response upon 
withdrawal of the SCD treatment. 
 
9.5.2. PROBABLY RELATED 
A clinical event, including a significant change in a laboratory test, that occurs 
within a reasonable time sequence in relationship to the SCD treatment or other 
protocol-required activity that is unlikely to be attributed to concurrent disease, 
other drugs, chemicals, or procedures, and that follows a clinically reasonable 
response upon withdrawal of the SCD treatment. 
 
9.5.3. POSSIBLY RELATED 
A clinical event, including a significant change in a laboratory test, that occurs 
within a reasonable time sequence in relationship to the SCD treatment or other 
protocol-related activity that could also be explained by concurrent disease, 
drugs, chemicals, or procedures. The clinical course after withdrawal of the 
SCD treatment may be unclear with respect to the contribution of the SCD 
treatment to the AE. 
 
9.5.4. UNRELATED 
An AE, including a significant change in a laboratory test, that occurs with a 
temporal relationship to the SCD treatment or protocol-required activity that 
makes an association with the SCD treatment or study activity improbable, and 
in which other drugs, procedures or underlying disease(s) provide likely 
explanation.  
 
9.6. SEVERITY – INTENSITY 




An event that requires minimal clinical treatment or an adverse event 
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9.6.2. MODERATE 
An event that requires non-routine intervention, (i.e., a new clinical 
treatment or diagnostic procedure), administered within an hour of the 
event; causes annoying discomfort. 
 
9.6.3. SEVERE 
An event requiring immediate intervention; causes significant discomfort. 
 
9.7. ADVERSE EVENT REPORTING 
Adverse event reporting requirements will be based on the time period in which 
the adverse event occurs. 
 
9.7.1. SCREENING PERIOD (CONSENT THROUGH RANDOMIZATION) 
Only adverse events, serious and not serious, directly related to the screening 
procedures will be capture during this period. Unrelated clinical adverse events 
that occur prior to randomization will be considered part of the medical history. 
 
9.7.2. RANDOMIZATION THROUGH END OF STUDY  
All adverse events that occur from the time of randomization/enrollment will be 
recorded as follows: 
 Serious Adverse Events (identified in 9.2) will be recorded until 
Day 60 after randomization, death, or patient withdrawal of study 
consent, whichever occurs first. 
 Non-serious adverse events will be recorded until Day 60 after 
randomization, death, patient withdrawal of study consent or until 
hospital discharge, whichever occurs first. 
 
Any serious adverse event (regardless of relationship to the treatment) occurring 
from the time of enrollment/randomization through end of study must be 
reported to CytoPherx Inc, or designee, within 24 hours of knowledge of the 
event.  This includes patients in the control arm. 
 
Each clinical trial site will be supplied with written SAE reporting instructions, 
SAE reporting forms and contact information for reporting of serious adverse 
events. 
 
For any AE that is ongoing at the time of the initial report, periodic follow-up 
information will be required until the adverse event is resolved or the patient is 
no longer in the study, whichever occurs first. 
 
The Investigator is responsible for all adverse events reporting to the 
Institutional Review Board (IRB) according to the requirements of the IRB and 
for providing clinical trial monitors with all medical records needed to source-
verify the adverse events.  
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10. CLINICAL EVENTS COMMITTEE  
A clinical events committee (CEC) will be in place to review and adjudicate certain 
events that occur. At the onset of the trial, the CEC will establish a charter that 
outlines the criteria for which an event requires review, the method in which the 
reviews will take place, and the minimum documentation required for reviews. The 
CEC will be made up of physicians based on their clinical expertise and experience 
on CECs. They will have no other association with this trial or the sponsor. The CRO 
will have the primary role in composing and managing the CEC.  
 
11. DATA SAFETY MONITORING BOARD   
An independent Data Safety Monitoring Board (DSMB) will review safety results 
over the course of the study on a schedule set by CytoPherx, Inc. and the DSMB. In 
addition, the DSMB will be provided with one formal interim statistical analysis on 
the primary endpoint of 60 day mortality, as detailed in the statistical analysis section 
below. The DSMB will comply with the FDA Guidance: ―Guidance for Clinical Trial 
Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring 
Committees‖. The DSMB will be formed to provide scientific and medical feedback 
for the study.  
 
The DSMB will focus on the following areas:  
 
 Performance – to assess study conduct and compliance; 
 Effectiveness – to assess mortality; 
 Safety – to assess the incidence, severity, relationship, and timing of 
adverse events and to identify safety concerns; and 
 Context – to assess the study relative to the AKI literature. 
 
The DSMB will consist of a minimum of 5 independent experts including a minimum 
of 4 clinicians and a biostatistician.  The DSMB will operate under a charter and will 
identify prospective data display specifications to conduct independent data reviews. 
The DSMB will make recommendations to the Sponsor to continue the study as 
planned or to stop the study due to safety or futility issues. The DSMB will meet to 
perform safety and effectiveness evaluations and to provide feedback to the Sponsor 
at least annually as well as after 25% and 50% of the cohort has completed 60 day 
follow-up. The DSMB reserves the right to request more frequent evaluations. 
 
12. STATISTICAL ANALYSIS  
12.1.    GENERAL CONSIDERATIONS 
The primary endpoint in this trial is time to all-cause mortality through 60 days 
post-randomization. The primary analysis is the assessment of difference between 
the experimental treatment (CRRT+SCD) and the control treatment (CRRT alone) 
on the primary endpoint, and the assessment of this difference will be carried out 
at an overall two-sided 0.05 level of significance. Statistical treatment 
comparisons on secondary endpoints will also be carried out at an overall two-
sided 0.05 level of significance, unless otherwise specified. Statistical analyses 
will be carried out using SAS version 9.1 or higher, and other appropriate 
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statistical software if necessary. 
 
12.2.    DETERMINATION OF SAMPLE SIZE  
The efficacy null and alternative hypotheses to be assessed are as follows: 
 
H0: λC+S = λC 
vs. 
H1: λC+S ≠ λC 
 
where λC+S and λC are the true 60 day mortality hazard rates for the CRRT+SCD 
and CRRT alone groups, respectively. The null hypothesis will be tested at the 
overall two-sided 0.05 level of significance at 80% power.  Under the 
assumptions: 
 
1. λC = 0.01155 when time to mortality is measured in days (leading to a 50.0% 
mortality rate at 60 days for CRRT alone);  λC+S = 0.00718 when time to mortality 
is measured in days (leading to a 35.0% mortality rate at 60 days for CRRT + 
SCD);  
 
2. As described in the SCD-003 Protocol, CytoPherx has assumed a mortality rate of 
50% for control and 35% for SCD. 
 
For the control mortality estimate, a 2004 publication [20]
 
 was used which 
summarized mortality data for subjects with acute renal failure (ARF) requiring 
renal replacement therapy (RRT) in the intensive care unit.  A table from this 
publication is reproduced below (Table 9).  In this table, the mortality of subjects 
who received CRRT (―Dialysis‖) is compared to those who did not (―% Mortality 
No Dialysis‖).  A weighted average was calculated by weighting the observed 
value for ―% Mortality Dialysis‖ by the number of subjects enrolled.  We found 
that the weighted mortality of subjects who received CRRT was 58.3%, based on 
this literature analysis of 5,810 subjects.   
 








Brivet et a l [26] 1996 360 Multicenter, France 43% 64% 
Liano et al [5] 1998 748 Multicenter, Spain 53% 79% 
De Mendonca et al [27] 2000 1411 16 countries, Europe NA 44% 
Silvester et al [28] 2001 299 Multicenter, Australia NA 47% 
Metniz et al [7] 2002 839 Multicenter, Austria 39% 63% 
Clermont et al [29] 2002 254 Pittsburgh, USA 23% 57% 
Guerin et al [30] 2002 587 Multicenter, France NA 71% 
Metcalfe et al [31] 2002 89 Multicenter, Scotland NA 74% 
Mehta et al [32] 2002 605 Multicenter, California USA 39% 61% 
PICARD [20] 2003 618 Multicenter, USA 24% 45% 
Table 9 Several recent studies of ARF in the ICU 
In our proposed pivotal study, the assumed 60-day mortality rate for subjects 
receiving CRRT only (control subjects) is 50%.  This is a conservative estimate 
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since, based on the literature, the actual control mortality rate might be expected 
to be slightly higher. 
 
The observed 60 day mortality rate for SCD therapy was 29.2% in the Pilot study 
with data available for 24 subjects.  For the pivotal study, we have increased the 
assumed mortality rate to 35% to allow for variability in response across a 
broader population of subjects and treatment centers; 
 
3. The statistical test to compare treatments is the log-rank test;  
 
4. The study will be carried out using an adaptive design approach; specifically, 
there will be one formal interim analysis on mortality using the log-rank test after 
50% of the subjects achieve 60 day follow-up (or would have achieved 60 day 
follow-up had they not died or prematurely withdrawn from the study ); 
treatments will be compared via the log-rank test at this interim analysis using the 
O’Brien-Fleming two-sided significance levels (0.00305) for the interim analysis 
(leaving a two-sided significance level of 0.049 for the final analysis); only 
subjects achieving 60 day follow-up (or who would have achieved 60-day follow-
up had they not died or prematurely withdrawn) will be used in the interim 
analysis; note that if significance is shown in the interim analysis, a decision to 
stop the trial will only be made after consultation with the FDA; if significance is 
not shown at this interim analysis, then the DSMB will be provided with sample 
size re-calculations required to maintain at least 80% power for a statistically 
significant CRRT+SCD effect by the end of the study, conditioned on the interim 
results (details are provided below). 
 
Then the required evaluable sample size is 166 subjects per group. To account for 
attrition, which is expected to be minimal, 172 subjects per group will be 
randomized. The sample size was calculated using the PASS 2008 software, taking 
into account the fact the study may be stopped for overwhelming efficacy at the 
interim analysis using the log-rank test at the O’Brien-Fleming significance level of 
0.00305. 
 
12.3.    ANALYSIS POPULATIONS  
Intent-to-Treat (ITT) Analysis Set: All randomized subjects. This is the primary 
analysis set on which primary and secondary efficacy endpoints will be 
evaluated. All subjects will be analyzed according to the treatment to which they 
were randomized. 
 
Per-Protocol Analysis Set: The subset of subjects from the ITT analysis set in 
whom randomized treatment was initiated, who received the treatment to which 
they were randomized, who did not violate the inclusion/exclusion criteria, and 
who did not prematurely withdraw from the study (except due to death) by 60 
days post-randomization. 
 
Safety Analysis Set: The subset of ITT subjects in whom treatment was initiated. 
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This is the primary analysis set for the safety analysis. Subjects will be analyzed 
according to treatment received. 
 
12.4.    DEMOGRAPHICS AND BASELINE CHARACTERISTICS  
Baseline characteristics will be descriptively summarized for all subjects by 
treatment group for the ITT analysis set. Continuous measures will be 
summarized with sample size, mean, median, standard deviation, minimum and 
maximum; categorical measures will be presented with the counts and percents of 
subjects in each category. No statistical tests comparing treatments at baseline 
will be performed. 
 
12.5.    PRIMARY ENDPOINT  
The primary endpoint in this trial is time to mortality through 60 days post-
randomization. The Kaplan-Meier curve of time (days) to mortality through 60 
days post-randomization will be presented, as will the Kaplan-Meier estimate of 
the 60 day mortality rate.  In addition, the raw number and percentage of subjects 
who died by 60 days will be presented by treatment group. Treatment groups will 
be compared on time to mortality through 60 days using the log-rank test. The 
analysis will be carried out for the ITT (primary) and Per-Protocol (secondary) 
analysis set.  It is anticipated there will be few randomized subjects who 
prematurely withdraw from the trial. Subjects who do not die will be censored at 
60 days or at the last known time alive, whichever is earlier. 
 
Due to one formal interim efficacy analysis following which the DSMB may 
recommend an increase in sample size (based on the observed treatment 
difference seen at the interim analysis) beyond the initially planned 172 
randomized patients (see Section 12.8 for details), the final analysis comparing 
treatments on the primary endpoint does not use the conventional log-rank test p-
value to determine if a statistically significant treatment difference exists.  Instead 
it uses a weighted test statistic, T*, proposed by Cui, Hung and Wang [33] in 
which the independent test statistics of the two stages (interim and final) are 
combined by pre-specified weights, w1 and w2 
 
= 1 – w1, where w1 is the 
proportion of the total initially planned number of patients at which the interim 
analysis is performed. In the present case the trial is designed for 172 randomized 
subjects per group with an interim analysis after 50% of the patients achieve 60 
day follow-up (or would have achieved 60 day follow-up had they not died or 
prematurely withdrawn). Thus, the planned information time proportions are w1 = 
50% for first stage and w2 = 1 – w1 = 50% for the second stage.   
 
Hence, two log-rank tests will be performed. The first (interim) log-rank test will 
be based on all patients who achieved 60-day follow-up (or would have achieved 
60 day follow-up had they not died or prematurely withdrawn) at the time of the 
interim analysis.  The log-rank test Z statistic for treatment effect from this model 
is denoted as Z
(1)
. The second log-rank test will be based on all patients in the full 
analysis set at the end of the study. The log-rank Z statistic for treatment effect 
from this model is denoted as Z
*
.   Then define  
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where t1 = ratio of observed number of patients at the interim analysis to the 
initially planned total required number of randomized patients (172); and t* = 
ratio of the number of randomzied patients at the end of the trial to the initially 
planned total number of randomized patients (172).  Z
(2)
 is independent of Z
(1)
 and 
captures the information about the treatment effect in Z
*




At the final analysis, the test statistic used to compare treatments will be the 




 as defined above, using the square root of the 
planned proportions (square roots of w1 and w2 where w1 = w2 = 1- w1 = 0.5) as the 
weights, respectively. Specifically, the weighted test statistic for the final analysis, 









This combined test statistic T
* 
will be used to test the treatment effect with respect 
to the primary outcome at the final analysis. This test statistic controls the overall 
type I error in the presence of a sample size increase. This has been confirmed by 
computer simulations.   
 
The above is the primary analysis on the primary endpoint.  Additional analysis 
on the primary endpoint will be as follows: to account for premature withdrawal 
from the study, the following analysis will also be performed on the ITT analysis 
set as a secondary sensitivity analysis:  For patients who prematurely withdrew 
prior to 60 days post-randomization, missing mortality status will be imputed 
before carrying out the treatment comparisons. Imputation of missing mortality 
status will be carried out using the multiple-imputation logistic regression 
procedure using clinically relevant baseline characteristics as risk factors in the 
regression model (these characteristics will be fully specified in the study’s 
statistical analysis plan). A total of 10 imputed data sets will be generated, and 
logistic regression comparing treatments on 60 day mortality status will be run on 
each data set. An assessment of overall treatment difference on 60 day mortality 
will then be generated from combining the logistic regression estimate of the 
treatment effect and the estimate of its standard error across the 10 data sets.  This 
will not be done at the interim analysis, but only at the final analysis, at the same 
final significance level as will be used for the primary analysis. 
 
For the primary (non-imputed) analysis on the ITT data set, the raw Kaplan-Meier 
estimates of mortality rate will be presented for each treatment group within each 
study center.  An assessment of treatment-by-study center interaction effect will 
be carried out using Cox proportional hazards regression containing the main 
effects of treatment and center and the interaction effect of treatment-by-center. A 
treatment-by-center interaction effect that is not significant at the 0.15 level of 
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significance, or that is significant but only quantitative in nature, will not preclude 
pooling of patients across study centers for the primary endpoint analysis. Prior to 
breaking the randomization blind, study centers with less than 10 subjects will be 
pooled with other study centers located in similar geographic regions.   
 
All enrolled patients will receive standard intensive care treatment for patients 
undergoing CRRT or CRRT+SCD. Any mode of CRRT will be allowed (CVVH, 
CVVHD, and CVVHDF) and the modality of CRRT is not expected to affect 
performance of the SCD. The modality-by-treatment interaction will be assessed.  
Specifically, for the primary (non-imputed) analysis on the ITT data set, the raw 
Kaplan-Meier estimates of mortality rate will be presented for each treatment 
group within each modality.  An assessment of treatment-by-modality interaction 
effect will be carried out using Cox proportional hazards regression containing the 
main effects of treatment and modality and the interaction effect of treatment-by-
modality. A treatment-by-modality interaction effect that is not significant at the 
0.15 level of significance, or that is significant but only quantitative in nature, will 
not preclude pooling of patients across modalities for the primary endpoint 
analysis. 
 
 12.6.    SECONDARY ENDPOINTS  
 Renal Replacement Therapy dependency at day 60
 Time-to-Mortality through day 28 
 Number of ventilator free days (VFD) at day 28 
    Time-to-Mortality through day 60 for the Severe Septic patient(s) 
 
Definitions for secondary endpoints are provided in Appendix D 
 
For renal replacement therapy dependency, treatments will be compared on the 
number and percentage of patients with the incidence of the event using the Z test 
for proportions or the continuity-corrected z-test for proportions, depending on 
event rate. For time-to-mortality through day 28 and for time to mortality through 
day 60 for the severely septic patient sub-population, treatments will be compared 
using the log-rank test.  For number of VFD at day 28, the sample size, mean, 
standard deviation, median, quartiles, and minimum and maximum will be 
presented for each treatment group. Treatment groups will be compared using the 
two-sample t-test. Health Economic endpoints are still under development will be 
discussed in a separate plan.  These endpoints are not intended to support a PMA 
application. 
 
In order to control the overall two-sided level of significance at 0.05 across the 
secondary endpoints, the Benjamini-Hochberg procedure will be used. For time-
to-mortality analysis, patients who did not die will be censored at the time of 
analysis (day 28 or day 60) or at the time of premature withdrawal, whichever is 
earlier.  Otherwise, given the secondary nature of these endpoints, no imputation 
for missing data will be performed; i.e., patients prematurely withdrawing prior to 
the time point at which the endpoint is measured will be excluded from the 
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analysis on that endpoint. 
 
12.7.    ADVERSE EVENT ANALYSIS  
Adverse event analysis will be performed on the safety population. Adverse 
Events (AEs) will be mapped to preferred term and body system using the 
Medical Dictionary for Regulatory Activities (MedDRA). Adverse Event listings 
will be provided for all AEs, SAEs, and all UADEs leading to study 
discontinuation.  
 
The number and percentage of patients experiencing AEs will be summarized by 
treatment group overall and for each System Organ Class and Preferred term. This 
analysis will be repeated for Serious AEs and for any AEs leading to 
treatment/study discontinuation.  AEs will also be tabulated by maximum severity 
experienced.  Treatments will be compared on incidence of AEs using Fisher’s 
Exact Test. 
 
12.8.    INTERIM ANALYSIS/ADAPTIVE DESIGN  
There will be one formal interim efficacy analysis on the primary endpoint of 
time to all-cause mortality by 60 days, to be inspected by the DSMB. This 
analysis will be performed on the ITT analysis set after 50% of the planned 
number of patients achieved 60 day follow-up (or would have achieved 60 day 
follow-up at the time if the patient did not die or prematurely withdraw). Using 
the Lan-DeMets function with the O’Brien-Fleming philosophy, the two-sided 
treatment comparison significance levels to be used at the interim and final 
analysis are 0.00305 and 0.049, respectively. If the DSMB recommends stopping 
the study at the interim analysis (i.e., if the two- sided p-value for the primary 
endpoint is below 0.00305 at the interim analysis), a decision to stop the study 
will only be made after consultation with the FDA.   
 
If the DSMB does not recommend stopping the study at the interim analysis for 
overwhelming efficacy, the DSMB may recommend stopping the study for futility 
if the interim estimate of survival for the CRRT alone group is larger than that for 
the CRRT + SCD group (in which case, no further enrollment of patients will be 
carried out, but patients already enrolled at the time of the decision to stop for 
futility will continue to be followed for 60 days.  Otherwise, the DSMB will be 
presented with a proposed increase in sample size for achieving a statistically 
significant treatment difference on the primary endpoint by the time of the final 
analysis.   The sample size re-estimation will be performed based on the approach 
suggested by Cui, Hung and Wang (1999) using the ratio of the initial estimate of 
effect size, E0, which is the difference between Kaplan-Meier estimates of 60 day 
mortality rate (CRRT + SCD minus CRRT alone) for the initial sample size 
determination used for study design, and the observed effect size, E, which is the 
treatment difference in estimated Kaplan-Meier estimate of the 60 day mortality 
rate at the time of the interim analysis.  
 
The number of patients initially estimated, No (=172), is readjusted to determine 
the new total number of required patients, N, using the following formula: 
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This method will provide the required number of patients for the second stage of 
the study. In case the sample size re-assessment results in an increase of the 
number of subjects, the DSMB may recommend changing the study accordingly 
(if however the increase in sample size is more than twice the number of 
originally planned subjects, the DSMB may recommend continuing the study 
until twice the number of originally planned patients are randomized).   In case 
the sample size re-assessment results in an adaption to less than the original 
planned sample size, the study will be continued as originally planned (until 172 
subjects are randomized). 
 
The statistical methodology used to compare treatments at the interim and final 
analysis is discussed above.  The overall type I error of 5% is controlled as has 
been confirmed by simulations. 
 
The DSMB will periodically review safety data.  A DSMB charter will be written 
outlining the safety data to be inspected periodically by the DSMB. The DSMB 
may recommend stopping the study for safety issues, and this recommendation 
does not need to necessarily be based on statistical significance. 
 
12.9.    EXPLORATORY ANALYSIS 
In addition a number of exploratory analyses will be conducted. No formal 
statistical hypothesis tests will be conducted. Predictors of survival will be 
assessed using Cox proportional hazards regression utilizing univariate and 
multivariate models to assess association of selected parameters with the primary 
outcome.  Some parameters to be assessed may include gender, age, 
race/ethnicity, presence of co-morbidities, type of CRRT modality, SOFA score 
and RIFLE predicted outcomes.  Additional regression models may include 
interaction terms for the selected parameters to assess for evidence of a 
differential treatment effect.  Other exploratory analyses on additional outcome 
measures will describe the following outcomes in the two randomized groups: 
infection as defined in Appendix D, pressor free days,recovery of renal function, 
SCD integrity, ICU LOS, Hospital LOS, duration of Renal Support, CRRT circuit 
life analysis and fluid removal analysis.  Continuous outcomes will be 
summarized with sample size, mean, median, standard deviation, minimum, 
maximum and 95% confidence intervals; categorical outcomes will be presented 
with the counts and percents of subjects in each category along with 95% 
confidence limits. Additional, non pre-specified exploratory analyses may also be 
conducted. 
 
13. ECONOMIC AND QUALITY OF LIFE (QOL) EVALUATION 
13.1. QOL AND ECONOMIC STUDY OBJECTIVES 
The specific objectives for the QOL and economic study are as follows: 
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 To assess health-related quality of life and health state utility between study 
groups 60 days after randomization.  
 To estimate the costs of the hospital admissions in which renal replacement 
therapy is initiated and compare between groups. 
 To measure major health care resource utilization from randomization to 60 
days and compare between groups. 
 To estimate total health care costs at 60 days and compare between groups. 
 To estimate long-term cost effectiveness of renal replacement therapy for 
acute kidney injury using the SCD, relative to providing renal therapy without 
the SCD. 
 
14. DATA COLLECTION – STUDY MONITORING AND AUDIT 
The Principal Investigator is responsible for assuring the accuracy and completeness 
of all study documentation.  Monitoring will be conducted within ICH/GCP 
Guidelines and CytoPherx, Inc. Clinical Monitoring Plan to ensure the following: 
 The facilities continue to be acceptable. 
 The protocol is appropriately followed. 
 Any agreed upon changes to the protocol have been approved by the IRB and 
approval has been received in writing by CytoPherx, Inc. 
 Accurate, complete and current records are maintained and available for all 
patients. 
 For each subject. collection of protocol-required data and entry of that data 
into the CRFs must be completed as soon as reasonably possible and shall not 
be more than 90 days following that subject’s last day in the study without 
permission from CytoPherx, Inc. 
 The information recorded and submitted to CytoPherx, Inc. is representative 
of the patient’s record and other supporting documentation. 
 Accurate, complete and timely adverse event reports for serious adverse 
events are submitted to CytoPherx, Inc. 
 The Principal Investigator continues to assume primary responsibility for the 
study. 
 
The Investigator or designee must, upon request, provide to the Clinical Research 
Associate (CRA), Quality Assurance Auditor, or FDA Investigator the necessary 
study records for a thorough review of the study’s progress.  These records include, 
but are not limited to, original documents and records, such as hospital and clinic 
charts, consent forms, and laboratory records.  The Principal Investigator is required 
to notify the Sponsor immediately of the following: 
 
 Withdrawal of IRB Approval 
 Any deviations from the protocol 
 Notification that Informed Consent was not obtained or consent was 
withdrawn 
 Any other instance in which the Investigator or Sponsor deems it necessary 
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15. INVESTIGATOR’S STATEMENT OF RESPONSIBILITY 
By my signature, I confirm that my staff and I have carefully read and understand this 
protocol and agree to comply with the conduct of the specified therein, In particular we 
have agreed to: 
 
 Conduct the study according to the protocol, amendments, and study guides. 
 Obtain Institutional Review Board approval of the study, any amendments to the 
study and periodic-re-approval, as required. 
 Obtain written consent from each study participant or their legal representative. 
 Report all serious adverse events to CytoPherx, Inc and to the IRB, as required by 
the protocol and IRB regulations. 
 Assure access by study monitors to original source documents. 
 Cooperate fully with any study-related GCP audit as performed by CytoPherx, Inc, 
their designee, or the Food and Drug Administration (FDA). 
 Maintain confidentiality and assure security of confidential documents such as the 
protocol, consent form, case report form, SCD Operator’s Manual, final study 







______________________________________   _______________ 
 







______________________________________     
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SEQUENTIAL ORGAN FAILURE SCORING SYSTEM (SOFA) [35] 
 
ORGAN SYSTEM MEASURE 
Respiration PaO2 to FiO2 Ratio 
Coagulation Platelet Count 
Liver Serum Bilirubin 
Cardiovascular Hypotension 
Central nervous system Glasgow Coma Score 
Renal Serum Creatinine or Urine Output 
 
MEASURE FINDING POINTS 
PaO2 to FiO2 Ratio 
(please see 
Pulmonary System 
Conversion Table for 
Non-ventilated Pts) 
≥ 400 mmHg 0 
300 – 399 mmHg 1 
200 – 299 mmHg 2 
100 – 199 mmHg 3 
< 100 mmHg 4 
Platelet Count 
≥150 x 103/mm3 0 
100 – 149 x 103/mm3 1 
50 – 99 x 103/mm3 2 
20 – 49 x 103/mm3 3 






< 1.2 mg/dL 0 
1.2 – 1.9 mg/dL 1 
2.0 – 5.9 mg/dL 2 
6.0 – 11.9 mg/dL 3 
≥12.0 mg/dL 4 
Hypotension 
Mean arterial pressure ≥70 mmHg 0 
Mean arterial pressure < 70 mmHg no 
pressor agents used 1 
Dobumatine any dose 2 
Dopamine ≤ 5 µg per kg per min 2 
Dopamine > 5 – 15 µg per kg per min 3 
Dopamine > 15 µg per kg per min 4 
Epinephrine ≤ 0.1 µg per kg per min 3 
Epinephrine > 0.1 µg per kg per min 4 
Norepinephrine ≤ 0.1 µg per kg per min 3 
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SEQUENTIAL ORGAN FAILURE SCORING SYSTEM (SOFA) 
 (Continued) 
 
MEASURE FINDING POINTS 
Glasgow Coma Score 
15 0 
13 – 14 1 
10 – 12 2 
6 – 9 3 
3 – 5 4 
Serum Creatinine or 
Urine Output 
Serum Creatinine < 1.2 mg/dL 0 
Serum Creatinine 1.2 – 1.9 mg/dL 1 
Serum Creatinine 2.0 – 3.4 mg/dL 2 
Serum Creatinine 3.5 – 4.9 mg/dL 3 
Serum Creatinine > 5.0 mg/dL 4 
Urine Output 200 – 499 mL per day 3 
Urine Output < 200 mL per day 4 
 
 
Conventions used for the above table include: 
 PaO2 is in mmHg and FiO2 in percent from 0.21 to 1.00. 
 Adrenergic agents as administered for at least 1 hour with doses in µg per kg per min. 
 A score of 0 indicates normal and a score of 4 indicates most abnormal. 
 Data can be collected and the score calculated daily during the course of the 
admission. 
 Mean systemic arterial pressure = systolic arterial pressure + twice the diastolic 
arterial pressure divided by 3.  All values should be in mmHg. 
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1. Minimum total score: 0 
2. Maximum total score: 24 
3. The higher the organ scores the greater the organ dysfunction. 
4. The higher the total scores the greater the multi-organ dysfunction. 
 
 MORTALITY RATE BY MODIFIED SOFA SCORE 
ORGAN SYSTEM 0 1 2 3 4 
Respiratory 20% 27% 32% 46% 64% 
Cardiovascular 22% 32% 55% 55% 55% 
Coagulation 35% 35% 35% 64% 64% 
CNS 26% 35% 46% 56% 70% 
Liver 32% 34% 50% 53% 56% 
Renal 25% 40% 46% 56% 64% 
 
 
GLASGOW COMA SCORE 
 
The Glasgow Coma Score (GCS) is scored between 3 and 15, 3 being the worst and 15 the best.  
It is composed of the three parameters listed below:  
 
Best Eye Response (4)    Best Verbal Response (5) 
1. No eye opening    1.   No verbal response 
2. Eye opening to pain   2.   Incomprehensible sounds 
3. Eye opening to verbal command 3.   Inappropriate words 
4. Eyes open spontaneously  4.   Confused 
5. Oriented 
 
Best Motor Response (6) 
1. No motor response 
2. Extension to pain 
3. Flexion to pain 
4. Withdrawal from pain 
5. Localizing pain 
6. Obeys commands 
 
A Coma Score of 13 or higher correlates with a mild brain injury, 9 to 12 is a moderate injury 
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SEQUENTIAL ORGAN FAILURE SCORING SYSTEM (SOFA) 
 (Continued) 
 
PULMONARY SYSTEM CONVERSION TABLE 
 
 
O2 Saturation Conversion Table  Conversion Table for FiO2 
Pulse oximetry O2 saturation may 
be used for calculating PaO2/FiO2 
ratio when ABG not available 
 When measured on mask or nasal cannula 
 
SaO2 (%) Calculated PaO2  Nasal Cannula 
80 44 100% O2 Flow Rate (L/min) FiO2 (%) 
81 45 1 24 
82 46 2 28 
83 47 3 32 
84 49 4 36 
85 50 5 40 
86 52 6 44 
87 53   
88 55 Oxygen Mask  
89 57 100% O2 Flow Rate (L/min) FiO2 (%) 
90 60 5-6 40 
91 62 6-7 50 
92 65 7-8 60 
93 69 9 90 
94 73 10 99+ 
95 79   
96 86 Mask with Reservoir Bag 
97 96 100% O2 Flow Rate (L/min) FiO2 (%) 
98 112 6 60 
99 145 7 70 
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APPENDIX B 
 
DEFINITIONS OF ACUTE KIDNEY INJURY/ACUTE TUBULAR NECROSIS  
 
      Acute Kidney Injury/Acute Tubular Necrosis 
 
Acute Kidney Injury (AKI) is sudden loss of the ability of the kidneys to excrete wastes, 
concentrate urine, and conserve electrolytes. 
 
Acute tubular necrosis (ATN) is defined in this protocol as AKI due to hemodynamic or toxic 
etiologies.  These conditions are found in circumstances of acute ischemic or nephrotoxic injury 
and conform to the following criteria: 
 
Oliguria: average < 20 mL/hour for > 6–12 hours           OR 
 
Serum Creatinine: ≥ to an increase of 2 mg/dL for males over a period of ≤ 4 days or ≥ to 
an increase of 1.5 mg/dL in females over a period of ≤ to 4 days 
(Note: pre-renal, hepatorenal, vascular, interstitial, glomerular, and obstructive etiologies 
are excluded on clinical or other diagnostic grounds.) 
 
ATN develops predominantly due to the injury and necrosis of HPTC (Human Proximal Tubular 
Cells).  ATN is caused by ischemia of the kidneys or by exposure to nephrotoxic agents. Risks 
for ATN include injury or trauma with resulting damage to the muscles, recent major surgery, 
blood transfusion reaction, septic shock or other forms of shock, and severe hypotension longer 
than 30 minutes.   
 
Any condition that causes a reduction in the amount of blood being pumped by the heart may 
cause ATN.  Liver disease and damage caused by diabetes mellitus (diabetic nephropathy) may 
predispose a person to the condition.  ATN can also be caused by exposure to nephrotoxic agents 
(e.g., aminoglycoside antibiotics), antifungal agents (e.g., amphotericin), medications to prevent 
rejection of transplanted organs (e.g., cyclosporine), dye used for radiographic studies, and other 
toxins.  In SCD studies, only patients with ATN due to hemodynamic or toxic etiologies are 
eligible for study participation.  As noted above, pre-renal, hepatorenal, vascular, interstitial 
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APPENDIX C 






Sepsis is defined in this protocol as a condition which has clinical evidence suggestive of 
infection, plus signs of a systemic response to infection with all of the following: 
 
 
Tachypnea > 20 breaths/min
1
 
Tachycardia  > 90 beats/min 
Hyper/Hypothermia  > 38.4˚C or < 35.6˚C 
            
1




B. SEVERE SEPSIS 
 






Metabolic acidosis Higher than upper limit 
Acute encephalopathy  
Oliguria <0.5 ml/kg for at least one (1) hour 
Hypoxemia or DIC
2
 or hypotension PaO2/fiO2 <280
3
 
<90 mmHg (or a 40 mmHg decrease 
below baseline) 
      
2
 Disseminated intravascular coagulation 
       
3
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RENAL REPLACEMENT THERAPY (RRT) DEPENDANCY AT DAY 60 
RRT dependency at day 60 is defined as patient not receiving any form of intermittent or 
continuous renal replacement therapy at 60 days post enrollment in the study with no plans for 
additional intermittent or continuous renal replacement therapy. 
 
NUMBER OF VENTILATOR FREE DAYS (VFD) AT DAY 28 
Ventilator Free Days (VFD) to day 28 is defined as the number of days of unassisted breathing to 
day 28 after randomization, assuming a patient survives for at least two consecutive calendar 
days after initiating unassisted breathing and remains free of assisted breathing. If a patient 
returns to assisted breathing and subsequently achieves unassisted breathing prior to day 28, 
VFD will be counted from the end of the last period of assisted breathing to day 28 unless a 
period of assisted breathing was less than 24 hours and the purpose of assisted breathing was a 
surgical procedure. If the patient is receiving assisted ventilation at day 28 or dies prior to day 
28, VFD will be zero (0). 
Unassisted breathing is defined as breathing with a face mask or nasal prong oxygen (or room 
air) following extubation, T-tube breathing, breathing with continuous positive pressure (CPAP 
≤ 5 cm H2O), or tracheotomy mask breathing. 
 
VASOPRESSOR USAGE 
Vasopressor usage will be determined by:   
1. Length of vasopressor treatment until day 28 or ICU discharge whichever comes first. 




Infection will be defined as "a positive body fluid (blood, sputum, urine, etc.), tissue (muscle, 
skin, etc.), or indwelling device (catheter tip, pacer lead, etc.) culture from non-contaminant 
pathogen." Infection rate is the total number of infection episodes up to hospital discharge or day 
60 (whichever comes sooner) per group.    
 
HOSPITAL LENGTH OF STAY: 
Both ICU and Hospital length of stay will be defined based on the ICU and acute hospital 
admissions during which the patient was randomized and enrolled in the SCD003 Trial. Length 
of stay will be evaluated on the basis of the mean number of days of ICU/hospital stay following 
randomization into the SCD003 trial.  Hospital discharge will be defined as discharge from acute 
care, whether to acute rehabilitation, transitional care, long term care or home. 
 
DURATION OF RENAL SUPPORT: 
The duration of renal support will be defined as the numbers of days from the initiation of renal 
replacement therapy to final dialysis treatment. Duration of renal support will be censored if the 
patient is still dialysis dependant at the time of death. 
 
RECOVERY OF RENAL FUNCTION: 
Recovery of renal function will be defined as lack of need for continuous dialysis support, and 
will be classified as complete recovery, partial recovery, or no recovery. 
          CytoPherx, Inc                                                                                                                                       Confidential 
       SCD003_ v1.4_October 24th _2011                                                                                                Page 53 of 66 
Complete recovery of renal function will be defined as serum creatinine that is no more than 0.5 
mg/dL greater than baseline; partial if the level remained above 0.5mg/dL above the baseline but 
not dialysis dependant. Patients who remain dialysis dependant at study completion or time of 
death will be categorized as having no recovery of renal function. 
 
SCD-ARF INTEGRITY: 
Selective Cytopheretic Device integrity is defined as use of the SCD-ARF without failure. The 
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Continuous Renal Replacement will be provided to all patients randomized in the SCD-003 Trial 
using automated equipment with integrated ultrafiltration control. All CRRT equipment will be 






CRRT Modality:   Continuous     
Blood Flow Rate:   Prescribed by Investigator Team – Treating Team 
Dialysate Type:   Prescribed by Investigator Team – Treating Team 
Dialysate Rate:   Prescribed by Investigator Team – Treating Team 
Replacement Fluid Type:  Prescribed by Investigator Team – Treating Team  
Ultrafiltration:    Prescribed by Investigator Team – Treating Team 
Anticoagulation:   Regional Citrate Anticoagulation Only 
Anticoagulation Prescription:  Prescribed by Investigator Team – Treating Team 
CRRT Device    B.Braun Diapact – Provided by Sponsor 
Hemofilter:    Fresenius Polysulfone® F50NR – Provided by Sponsor  
CRRT System Change:  Per participating center protocol 
SCD Change:    Every 24 hours or as needed due to clotting 
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APPENDIX F 
CHILD-PUGH LIVER STAGING 
 
Parameters: 
(1) Serum total bilirubin 
(2) Serum albumin 
(3) Prothrombin time 
(4) Grade of hepatic encephalopathy 
(5) Ascites 
 
PARAMETER FINDING POINTS 
Total Bilirubin < 2 mg/dL 1 
 2 – 3 mg/dL 2 
 > 3 mg/dL 3 
   
Serum Albumin > 3.5 g/dL 1 
 2.8 – 3.5 g/dL 2 
 < 2.8 g/dL   3 
   
Prothrombin Time (seconds) 
Prolonged 1 – 4 sec prolonged 1 
 4 – 6 sec prolonged  2 
 > 6 sec prolonged 3 
   
Grade of Hepatic Encephalopathy None 1 
 Grade 1 or 2 2 
 Grade 3 or 4 3 
   
Ascites None 1 
 Mild 2 
 Severe Tense 3 
 




GRADE TOTAL SCORE RISK 
A 5 or 6 Good 
B 7–9 Moderate 
C 10–15 Poor 
 
Minimum score: 5; maximum score: 15  
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APPENDIX G 
SCD-003 Study Schedule of Events  
 
















Vital Signs/Physical Assessment  
  Temperature , Body Weight X X X X X X X X 
 
  Blood Pressure, Heart Rate X q4h q4h q4h q4h q4h q4h q4h 
  EKG X        
  Sequential Organ Failure Assessment (SOFA Score) X X X X X X X X 
  Physical Exam X  
  Urine Output  X X X X X X X X 
  Net fluid balance (24 hours)  X X X X X X X  
Clinical Laboratory Testing 
  CBC with differential X q8h q8h q8h q8h q8h q8h q8h  
  BUN/Creatinine X X X X X X X X  
  Na, K, Cl, HCO3, Ca, Mg, PO4, Ionized Calcium X X X X X X X X  
  Haptoglobin X        X 
ALT, AST, LDH, Bilirubin, ALP, TP, Albumin, Glucose X X X X X X X X  
  PT, PTT, INR X X X X X X X X  
  Urinalysis (if urine is available) X         
Respiratory 
  Arterial Blood Gas (pH, PaO2, PaCO2) (if on vent)* X q4/q12h q12h q12h q12h q12h q12h q12h  
  Ventilator Settings (Mode, FiO2, TV, PEEP, RR, NO)                  X q4/q12h q12h q12h q12h q12h q12h q12h  
  Non-ventilator Settings (Face mask, supplement O2, etc) X q4/q12h q12h q12h q12h q12h q12h q12h  
Blood For Research 
  Blood for Biomarkers X X (hr24)  X (hr 72)  X (hr 120)  X (hr 168) X 
Extracorporeal Device Parameters 
  CRRT (Settings) X (hour 0) q6h q6h q6h q6h q6h q6h q6h  
  Post Filter Ionized Calcium X (hour 0) q6h q6h q6h q6h q6h q6h q6h  
  CRRT Device and SCD-ARF Performance (Event Driven)  X X X X X X X  
Other (Event-Driven) 
  Adverse Events  X X X X X X X X X 
  Concomitant Medications, Blood products X X X X X X X X X 
  Diagnosis/Therapeutic Procedures X X X X X X X X X 
  Microbiology/culture data X X X X X X X X  
*Time points are different depending on the presence of an A-line; see section 6.3 and 6.4 for details
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APPENDIX H 
SCD-003 Study Schedule of Events: Follow-up Period 




0 - 24 
Hours  
25 – 1681 
Vital Signs/Physical Assessment  
Blood pressure and heart rate X X 
SOFA Score (daily until ICU discharge or Day 28) X X 
Physical Exam X  
Body weight and temperature X X 
EKG  X  
Urine Output (from previous 24 hours)  X X 
Net Fluid Balance – (from previous 24 hours) (until ICU 
discharge or Day 28)    
X X 
Clinical Laboratory Tests   
CBC with differential  X  
BUN/Creatinine  X  
Na, K, Cl, HCO3, Ca, Mg, PO4, Ionized Calcium X  
Respiratory:    
Arterial Blood Gas  (pH, PaO2, PaCO2)
2
 X X 
Ventilator Settings (Mode, FiO2, TV, PEEP )                  X X 
Non-ventilator Settings (Face mask, supplement O2) X X 
Other (event driven)  
Renal Replacement Therapy status X X 
Medications given  X X 
Pressor Usage (until ICU discharge or Day 28) X  
Procedures performed X X 
Adverse events X X 
Microbiology/Culture Data (until Hospital Discharge or Day 60) X X 
 
       1Events listed in this column are to be performed once per 24 hour time period 
 
2
If on vent with an arterial line 
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APPENDIX I 







Blood pressure, heart rate and temperature (if known) X X 
Presence of mechanical ventilation (since last visit) X X 
Presence of renal replacement therapy (since last visit) X X 
SOFA (if still in ICU)
3 X 
 
Fluid Balance (if still in ICU)
3 X 
 
Pressor Usage (if still in ICU)
3 X 
 
Microbiology/Culture Data (if still in Hospital)
3 X X 
Hospital and ICU Discharge information  X X 
Adverse events X X 
Serum Creatinine (if office visit takes place) X X 





1 This visit may be done via telephone call or office visit. Please record the above information on 
day 28 (+7 days) following enrollment. 
 
2 
This visit may be done via telephone call or office visit. Please record the above information on 
day 60 (+7 days) following enrollment. 
 
3
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APPENDIX J 
INFORMED CONSENT TEMPLATE 
A Multi-Center, Randomized, Controlled, Pivotal Study to  
Assess the Safety and Efficacy of A Selective Cytopheretic 
Device (SCD) In Patients with Acute Kidney Injury (AKI)  
 
Informed Consent Statement 
STATEMENT OF RESEARCH 
 
You, or your family member, may be eligible to take part in a research study using a new 
medical device called the Selective Cytopheretic Device (SCD).  You may decide to be in 
the study or decide not to take part at all.  It is your decision.  If you decide to be in the 
study, you may withdraw or stop the study at any time.  No matter what you decide, your 
decision will not lead to any penalty or affect your regular medical care from the doctors 
and hospital staff.  This document describes what will be done to you should you decide 
to participate and any risks that might be involved in this study.  It is important that you 
read the following information and ask as many questions as necessary to be sure you 
understand what you will be asked to do. 
 
INFORMATION ABOUT AKI AND THE STUDY DEVICE 
 
You, or your family member, have been diagnosed with a very serious and often deadly 
disease known as acute kidney injury (AKI).  AKI is a condition where the kidneys are 
not able to make enough urine.  Therefore another way to remove waste from your body 
is needed. One way of removing waste from the body is called Continuous Renal 
Replacement Therapy (CRRT). There are different types of CRRT, but all allow waste to 
be removed from your body because your kidneys can not do this any longer.  Your 
doctor has recommended this therapy for you or your family member. You may already 
be receiving CRRT or you are about to begin. 
 
Acute kidney injury can also cause your immune system to not work correctly. Your 
immune system usually helps your body get better, but having an immune system that 
doesn’t work may be one of the reasons that AKI is such a morbid and deadly condition.  
White blood cells, which are key parts of the immune system, are overactive in AKI and 
may be the reason your immune system isn’t working the way it should.   
 
While we don’t know the exact reason the device in this study, the SCD, may help you, it 
is thought it binds and stops overactive white blood cells. When the white blood cells are 
in the SCD they come in contact with a medicine called citrate. Citrate is sometimes used 
in patients that need CRRT. It is an anticoagulant, meaning that it stops your blood from 
clotting while it is going through the CRRT machine. Should you choose to be a part of 
this study, your doctors will use citrate as part of your CRRT treatment whether you are 
treated with the device or not. 
 
If you decide to participate, you will be placed into one of two study groups. Half (50%) 
of the subjects in the entire study will placed on the SCD and the other half will not. 
Whether you will be treated with the SCD is completely random (like flipping a coin). 
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Your doctors and other caregivers do not decide which group you will be in. However, 
you will know which group you are in when the study tests begin. 
 
PURPOSE OF RESEARCH AND LENGTH OF PARTICIPATION IN STUDY 
 
The purpose of this study is to test if the SCD helps someone with AKI recover faster 
than without it. 
 
You will remain in the study for 60 days after you begin the study unless you choose to 
stop before that.  
 
Up to 344 subjects will take part in this study at up to 30 centers.  
 
THIS IS WHAT WILL HAPPEN IF YOU DECIDE TO BE IN THIS RESEARCH STUDY 
 
Should you decide to participate, your doctor or a member of the study team will ask you 
to sign this informed consent document. They will then talk to you about your disease 
and ask you questions about your health.  They will determine if you meet the conditions 
for the study. It is possible that after looking at your medical history or your current 
condition, they may discover that you are not able to join the study. Some studies have 
specific requirements for being a part of the study. If this happens, no data will be 
collected from you and your healthcare treatment will continue as if you were never 
asked.  
 
Beginning of study: 
If the study team believes you are able to be a part of this study, they will enroll you into 
the study and you will be put into the SCD (study) group or the non-SCD (control) group 
by a completely random process that the medical staff has no control over. No matter 
which group you are in, medical information about you will be collected for the study. 
The study team will look at your medical records, complete a physical exam and EKG, 
and a few blood tests will be performed. An EKG is a test that shows the doctors how 
your heart is beating. Most of the blood tests that will be done are routine blood tests that 
are done on someone with AKI, but we will also be taking a small amount of blood that 
will be sent to an outside laboratory and tested for different biomarkers of kidney injury. 
A biomarker is something that shows up in the blood that may indicate a health problem. 
This could help future patients with acute kidney injury. 
 
Observation/Treatment Period: 
If you are in the SCD group, the study device will be connected to the CRRT tubing so 
there are no extra needle sticks or extra tubes that need to be inserted in your body. At all 
times while the study device is running trained medical personnel will be at your bedside 
to make sure the SCD is working properly.  The study device may be connected for as 
long as 7 days. It will be stopped earlier if your kidneys have recovered, your doctor 
thinks it is necessary, you decide that you longer wish to participate or if there is any 
evidence that the device is not working properly.  
 
If you are in the control (non-SCD) group, you will be placed on the same CRRT 
machine, however there will be no SCD device connected to you. 
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In all patients, certain tests will be performed during the time you are on the study device 
or on CRRT (up to 7 days). They include things like taking your blood pressure and 
temperature, and collecting information about your general medical condition and what 
medications you are receiving. Blood tests will also be performed daily. Some blood tests 
are tests that are normally done on someone with AKI or are done for safety reasons. We 
will also be taking a small amount of blood that will be sent to an outside laboratory and 
tested for different biomarkers. This will allow us to see how the SCD is working.  
 
Follow-up Period: 
After you are taken off CRRT or you have been on CRRT for 7 days, you will remain in 
the study until you have been in the study for 60 days, even if you are discharged from 
the hospital.  
 
In the first 7 days after the observation/treatment period, information will be collected 
regarding your medical condition and what medications you have been given. An EKG, 
physical exam and blood tests will also be done on the first day after the observation 
period. These tests are typical of a patient in the hospital with AKI. If you remain in the 
ICU after this time, additional blood tests and clinical information may be collected.  
 
The final follow-up study visits will occur at 28 days following the start of the study and 
again at 60 days following the start of the study. The study team may have you come 
back to the hospital or office for this visit, or they may contact you by telephone. They 
will ask you questions about your health since the last visit. If you are in the doctor’s 
office or hospital, they will collect some vital signs and possibly do a blood test to see if 
your kidneys are working properly. 
 
You will also be asked to complete a short questionnaire towards the end of the study. 
There will be questions asking you about how you feel and how your health is affecting 
your everyday activities. You do not have to answer any questions that you don’t want to. 
The study staff may have you mail the form back in or may ask you to complete it in 
person or over the phone.  
 
The research staff will review your medical records from the time you were in the study. 
After your 60 day visit, you will no longer be part of the study and no more information 




There is no guarantee that you may receive any benefit from participation in this study.  
If you are in the SCD group, the SCD may help resolve or moderate your disease.   
 
While there may not be a direct benefit to you for participation in this study, the 
knowledge we will learn may benefit others in the future.  The information gathered in 
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Any experimental or test therapy is associated with risk. Some of these risks are not 
known.  
Possible side effects with the SCD is a decrease in your blood pressure, a decrease in the 
number of white blood cells and platelets in your blood (platelets are cells that help your 
blood clot), or bleeding.  In some cases any of the side effects could be life threatening.  
You will be closely monitored by the study team and your regular hospital caregivers. 
 
This product has not been tested in pregnant females.  Therefore, risks to an embryo or 
fetus are unknown at this time.  You should not be pregnant or intend to become pregnant 
while taking part in this study.  If you are a woman of child bearing potential, a 
pregnancy test will be performed before you enter the study. If you suspect that you have 
become pregnant during the study, you must notify the study doctor immediately.   
 
There is a risk of blood clotting in the SCD or CRRT tubing. To prevent blood clotting, 
regional citrate anticoagulation is used in the study. Citrate is not toxic and is also 
produced in small amount in the human body. 
 
A rare, potentially serious risk would be severely low or high blood calcium levels. This 
could happen if you receive too much calcium, citrate, or dialysis solution. This risk is 
lowered by the close monitoring of the citrate procedure. In addition, your blood will be 
tested for calcium levels.  
 
There are risks associated with the blood draw. It may be associated with discomfort, 
bruising, infection at the site and formation of a blood clot. All efforts will be made to 
collect these samples at the same time as your routine (non-study) blood draws. Also, if 
you have an arterial line in place, blood may be collected from there.  
 
There is a risk of the loss of confidentiality. The researchers will make every effort to 
keep your medical records safe and you will have a study number that will be used to 
identify you. 
 
Participating in this study could cause you some inconvenience.   
 




If you are in the SCD group, you may decide to stop being treated with the SCD at any 
time. If you decide to stop the SCD treatment, we may ask you to continue in the follow-
up period to gather safety information on you. However, you may also decide to leave the 
study completely.  
 
If you leave the study before the 60 days, there will be no penalty to you. You will not 
lose any benefits to which you may otherwise be entitled.  
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All information collected up to that point will remain in the study, but no further 
information will be collected. If you choose to tell the researchers why you are leaving 
the study, your reasons for leaving may be kept as part of the study record.   
 
Your doctor may also decide to remove you from the study if you don’t follow 
instructions or your condition changes while you are taking part in the study and the 
doctors feel that it is not in your best interest to stay in the study.  You may also be taken 
out of the study early if the study is suspended or canceled.  
 
If you leave the study early for any reason, your doctor may ask you to return for one or 
more study visits to complete the final study activities for safety reasons.  
 
Any significant new research findings regarding the study device that may affect your 
willingness to participate or continue in this study will be provided to you as updated 
information. 
 
WHAT OTHER OPTIONS ARE THERE? 
 
You do not have to participate in this study and can continue with your usual AKI 
treatments. Talk to your doctor about your choices before you decide if you will take part 
in this study. 
 
WILL IT COST TO PARTICIPATE? 
 
We do not expect there to be any additional costs to you if you participate in this study. 
You or your health plan will pay for all the things you would have paid for even if you 
were not in the study, including the ICU stay, CRRT, and other hospital related health 
costs.  The SCD study device will be provided by the sponsor at no cost to you or your 
health insurance provider.   
 
WILL I BE PAID TO PARTICIPATE?  
 
There is no payment made or financial benefit to you for taking part in this study. You will 
also not receive any money or other benefits as a result of any products, procedures, or 
other items developed from the results of this study. 
 
WHAT IF I AM INJURED? 
 
If you are injured as a direct result of being in this study and not due to the natural course 
of an underlying disease or treatment process, necessary medical care will be provided to 
you. It is possible that the costs of this medical care may be billed to your insurance 
company. However, if your insurance company does not pay these costs or if you do not 
have insurance, the study sponsor, CytoPherx, Inc. will cover the costs of your medical 
treatment necessary to diagnose and/or treat your injury.  CytoPherx, Inc. has no plans to 
pay for such things as lost wages, disability, or discomfort due to the injury.  No other 
compensation is routinely available.  You are not giving up any of your legal rights by 
signing this consent form. 
          CytoPherx, Inc                                                                                                                                       Confidential 







Although every reasonable effort will be made to protect the confidentiality of your 
records, such protection cannot be guaranteed. We shall put the information collected 
about you during the study into a research record.  This research record will not show 
your name, but will have codes entered in it that will allow the information to be linked to 
you.  Your medical information will be kept confidential by the study doctor and staff 
and will not be made publicly available unless disclosure is required by law. 
 
We may collect and use: 
 Your existing medical records 
 New health information created during this study 
 Health insurance and billing information (a separate billing release authorization    
may be required, but is not necessary for participation) 
 
We may release this information to the following people: 
 The Principal Investigator and his/her associates who work on, or oversee the 
research activities 
 The research sponsor company, CytoPherx, Inc, it’s Contract Research 
Organization (CRO), and any authorized consultants  
 Government officials who oversee research   
 
Data and information obtained from this study that does not identify you individually 
may be published in medical journals or presented at medical conferences.  By signing 
this consent form, you authorize the record review, information storage, and data transfer 
described above. 
 
Once your information has been released according to this consent form, it could be 
released again and may no longer be protected by federal privacy regulations. 
 
This consent form, test results, medical reports and other information about you from this 
study may be placed into your medical record. Generally, you are allowed to look at your 
medical record.  
 
This consent to use and release your personal and health information will expire at the 
end of this research study.  
 
You do not have to sign this consent to release your medical information and may cancel 
it at any time. If you decide not to sign this consent or cancel your consent, you cannot 
participate in this study. If you notify us that you wish to stop participating in this study, 
we may continue to use and release the information that has already been collected.  To 
cancel your consent, send a written and dated notice to the principal investigator at the 
address listed on the first page of this form.  
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A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as 
required by U.S. Law. This Web site will not include information that can identify you. 
At most, the Web site will include a summary of the results. You can search this Web site 
at any time. 
FUTURE BLOOD TESTING 
 
Researchers in this study are dedicated to researching biomarkers of kidney disease 
related to AKI. The data and blood samples collected during this study are important to 
this study and to future AKI research. With your additional consent, blood collected 
during this study (at the start of treatment and during the observation period) will be kept 
in an outside laboratory for an indefinite period of time with samples from other subjects 
who have consented to be in this study. All personally identifying information will be 
removed from the samples. They will be identified only by a unique study number.  
 
These samples may be used in the future in ongoing research related to biomarkers 
involved in AKI and other kidney conditions. They will only be studying kidney disease, 
which you have already been diagnosed as having. They will not be researching non-
kidney related disease.  
 
These samples will be sent an outside laboratory chosen by the sponsor, CytoPherx, Inc, 
but we will not give them any information that would personally identify you. We will 
not put the results of any tests conducted on these samples in your medical record. You 
may still participate in this study even if you do not agree to participate in the 
sample repository. 
 
[    ] _____________ (check box and initial) I AGREE to allow my blood samples to be 
saved for future biomarker studies.  
 
[    ] _____________ (check box and initial) I DO NOT AGREE to allow my blood 
samples to be saved for future biomarker studies. (Please note that your blood will still be 
sent out and tested for the current biomarkers as explained above, but your samples will 




WHO DO I CALL WITH QUESTIONS ABOUT THE STUDY OR TO REPORT AN INJURY? 
 
________________ MD or his /her staff member has explained this research study and 
has offered to answer any questions. If you have questions about the study procedures, or 
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CONSENT 
 
Volunteer’s Statement  
 I voluntarily agree to participate in this study. 
 I understand that the study sponsor, CytoPherx Inc. may stop the study at any 
time.  If this happens, I will no longer receive the study treatment and planned 
evaluations. 
 I have read and understand this statement of informed consent and the risks 
described. 
 I understand that I will receive a signed and dated copy of this consent form. 
 I understand that I may withdraw my consent at any time. 




Signature of Study Volunteer       Date 
 
________________________________________________   





Signature of Legally Authorized Representative    Date 
 
________________________________________________   






Signature of Person obtaining Informed Consent    Date 
 
________________________________________________   
Printed Name of Person obtaining Informed Consent     
 
 
 
 
